

Transfusion

Blood transfusion

NICE guideline

Appendices O-P-Q-R

18 May 2015

Draft for consultation

*Commissioned by the National Institute for
Health and Care Excellence*

Disclaimer

Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and, where appropriate, their guardian or carer.

Copyright

National Clinical Guideline Centre, 2015

Funding

National Institute for Health and Care Excellence

Contents

Appendices O-P-Q-R.....	775
Appendix O: Research recommendations.....	776
Appendix P: Excluded clinical studies	783
Appendix Q: Excluded economic studies	799
Appendix R: NICE technical team	803
References	804

Appendices O-P-Q-R

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27

Appendix O: Research recommendations

O.1 Red blood cell thresholds and targets

What is the clinical and cost effectiveness of restrictive compared with liberal red blood cell thresholds and targets for patients with chronic cardiovascular disease?

Why this is important:

The literature suggests that there may be some evidence of harm with the use of restrictive Red Blood Cell thresholds in populations with coronary ischaemia at baseline. In this guideline a level of 80–100 g/litre was used for patients with acute coronary syndrome, but further studies are needed to determine the optimal transfusion threshold for patients with chronic cardiovascular disease.

Criteria for selecting high-priority research recommendations:

PICO question	<p>Population: Patients with chronic cardiovascular disease in whom a decision is made to transfuse red cells.</p> <p>Intervention and Comparison: ‘Liberal’ and ‘restrictive’ transfusion triggers for red cell transfusion based on the pre-transfusion haemoglobin concentration (possibly 10g/dl for the ‘liberal transfusion strategy’ and 8g/dl for ‘restrictive’).</p> <p>Outcomes: Primary outcome: RBC use from randomisation to hospital discharge (proportion of patients receiving red cell transfusion and number of units of red cells/transfused patient).</p> <p>Secondary outcomes</p> <ol style="list-style-type: none"> 1. Use of non-RBC blood products post-randomisation (FFP; cryoprecipitate; platelets) 2. Mortality (hospital; 90 days) 3. HRQoL (90 days) 4. ICU and hospital length of stay
Importance to patients or the population	The research could be used to formulate evidence-based guidance for clinical staff that in turn will assist in reducing donor exposure to patients by giving specific transfusion triggers for clinical staff. By promoting a consistent approach nationally this would improve patient safety and allow benchmarking of patient outcomes.
Relevance to NICE guidance	The results would ensure that implementation of specific red blood cell thresholds based on evidence allowing improved clinical and cost effectiveness.
Relevance to the NHS	The study would provide evidence to guide clinicians on use of either high or low red cell thresholds across the NHS. It would also assist in showing which threshold best supports patient safety and best outcomes. More optimum use of blood products would ensure these are available for those in whom greatest clinical benefit occurs. Variation in clinical practice and patient care in relation to blood product transfusion will be reduced.
National priorities	
Current evidence base	The overall quality of current clinical evidence was very low in being inconsistent

	with each paper aiming for specific haemoglobin targets. There was high risk of bias found.
Study design	<p>Randomised Controlled Trial in patients with chronic cardiovascular disease. Patients randomised to low thresholds vs. high thresholds for red cell transfusions.</p> <p>Studies of specific patients groups such as surgical and medical should be collated and analysed, areas of research could include patients who have undergone similar surgical procedures or the same underlying medical conditions. A comparison should be undertaken by randomly selecting low/high thresholds targets and reviewing outcomes e.g. hospital stay, complications etc. Work to specific guideline for each group.</p>
Economic considerations	If the findings show low haemoglobin thresholds and targets are effective this will mean financial savings of 1 or 2 units of red cells per patient.
Feasibility	<p>This research should be completed within a reasonable timescale.</p> <p>May have to consider ethical issues if using high and low thresholds most of the research papers used specific target haemoglobins for their patient groups.</p>
Equalities	No specific equality issues identified
Importance	None.

1
2

1 O.2 Electronic Decision Support

2 **What is the clinical and cost effectiveness of electronic decision support systems compared with**
3 **current practice in reducing inappropriate blood transfusions, overall rates of blood transfusion**
4 **and mortality?**

5 **Why this is important:**

6 The clinical evidence evaluating electronic decision support systems is of low quality. There is also
7 no evidence on their cost effectiveness within the NHS, and this is particularly important because
8 of the potentially high setup and running costs of these systems. An evaluation of the clinical and
9 cost effectiveness of electronic decision support systems for blood transfusion is needed.

10 Important outcomes are rates of inappropriate transfusion, overall rates of transfusion, and
11 patient safety outcomes including mortality and transfusion errors. Secondary outcomes should
12 include length of hospital stay and quality of life; and pre-transfusion haemoglobin levels, platelet
13 count and coagulation results.

PICO question	Population: Patients in whom a request for red cells or other blood products is made Intervention: Electronic decision support system specific to blood transfusion Comparison: Existing blood transfusion request procedures (excluding electronic decision support systems) Outcomes: inappropriate blood transfusion; overall rates of blood transfusion; mortality; hospital length of stay; quality of life; pretransfusion haemoglobin level (for red cell transfusion), pretransfusion platelet count (for platelet transfusion), coagulation results (for plasma and coagulation factor transfusion)
Importance to patients or the population	Reduction in inappropriate blood transfusion will reduce risk to patients, and improve clinical outcomes. Reduction in overall use of blood products will reduce costs to the NHS, and increase availability for the population. Cost-effective systems will reduce cost to the NHS as well as improve patient outcomes.
Relevance to NICE guidance	The results would ensure that implementation of electronic decision support was based on evidence of clinical and cost effectiveness.
Relevance to the NHS	The study would provide evidence to guide whether the electronic decision support systems for blood transfusion should be introduced across the NHS. The benefits for patients and the health service in terms of improved outcomes and safer use of blood products would result in more optimum use of blood products and greater consistency between individual patients and clinicians. More optimum use of blood products would ensure these are available for those in whom greatest clinical benefit occurs. Variation in clinical practice and patient care in relation to blood product transfusion will be reduced.
National priorities	
Current evidence base	The overall quality of current clinical evidence was very low. No evidence relating to quality of life or the impact on pretransfusion haemoglobin, platelet, or coagulation tests was identified. No evidence concerning the cost effectiveness of electronic decision support systems was identified.
Study design	A variety of study designs may be appropriate. These could include parallel group randomised trials, cluster randomised trials, or other forms of evaluation. Studies should include all patients in whom blood transfusions occur, and may need to specifically account for important subgroups, for example urgent versus nonurgent transfusions, transfusions of red cells or platelets or plasma, and specific NHS settings.
Economic	An electronic decision support system would be implemented at hospital/blood

considerations	bank level. Economic evaluations need to account for an institution level perspective in addition to an individual patient perspective. Cost effectiveness analysis needs to acknowledge that subsequent implementation would require investment within multiple institutions within the NHS.
Feasibility	This research should be completed within a reasonable timescale. There are technical issues over trial design but it is unlikely there would be ethical problems. Specific consideration of the consent procedures required is relevant, as individual patient consent is unlikely to be feasible.
Equalities	No specific equality issues identified
Other comments	None.

1

1 O.3 Post-operative cell salvage following cardiac surgery

2 **For patients having cardiac surgery with a significant risk of post-operative blood loss, is post-**
3 **operative cell salvage and reinfusion clinically and cost effective in reducing red blood cell use**
4 **and improving clinical outcomes, compared with existing practice?**

5 **Why this is important:**

6 There was some evidence for benefit from post-operative cell salvage, but the quality was low.
7 Reducing blood loss during cardiac surgery may reduce the risk of complications. However, post-
8 operative cell salvage carries additional cost. Studies are needed to determine whether post-
9 operative cell salvage is more clinically and cost effective than existing practice for patients having
10 cardiac surgery with a significant risk of post-operative blood loss. Important outcomes should
11 include the use of red blood cells and other blood products, clinical outcomes and quality of life.

PICO

Population

Patients undergoing coronary artery bypass surgery and/or valvular surgery
Patients in whom overall perioperative blood loss is expected to be >500mL
Patients considered to be at risk of significant post-operative blood loss based on pre-operative and/or intraoperative factors

Intervention:

The intervention is a device, namely the use of a post-operative cell salvage system that collects shed blood from post-operative chest drains, washes, and haemoconcentrates the RBCs, and re-infuses via a venous cannula.

All patients should receive intraoperative interventions to minimise blood loss and RBC transfusion according to NICE guidance, namely the use of tranexamic acid and, for selected cases, intraoperative cell salvage.

All patients will receive RBC transfusions during the post-operative ICU period according to a protocol consistent with recommendations in the NICE guidance

The intervention groups will receive post-operative cell salvage from chest drains, with re-infusion following RBC processing until bleeding has stopped or a clinical decision to discontinue post-operative cell salvage is made

Comparator:

All patients should receive intraoperative interventions to minimise blood loss and RBC transfusion according to NICE guidance, namely the use of tranexamic acid and, for selected cases, intraoperative cell salvage.

All patients will receive RBC transfusions during the post-operative ICU period according to a protocol consistent with recommendations in the NICE guidance

The comparator group will NOT receive post-operative cell salvage from chest drains.

Outcomes:

Primary outcome:

RBC use from randomization to hospital discharge

Secondary outcomes

Haemoglobin concentration at ICU discharge

Use of non-RBC blood products post-randomization (FFP; cryoprecipitate; platelets)

	<p>Reoperation rate Mortality (hospital; 90 days) HRQoL (90 days) ICU and hospital length of stay A cost-effectiveness analysis should be incorporated.</p>
Study Design	<p>To define the at risk population a systematic review of available literature to define risk factors for post-operative risk of bleeding should be undertaken</p> <p>If necessary, new research to define the at risk population, for example to develop a risk score, should inform the RCT design</p> <p>The main trial should be a randomized parallel group design, with concealment of outcome assessors for the outcomes if feasible</p>
Timeframe	No specific timeframe
Importance to patients or the population	<p>Cardiac surgery utilises a high proportion of the UK blood supply. Wide variation in blood use remains between individual patients, surgeons, and hospitals. RBC transfusion has been associated with adverse outcomes in cardiac surgery, but it is uncertain whether this association is causative. NICE guidance will recommend tranexamic acid is offered to all patients undergoing cardiac surgery in whom blood loss is expected to be greater than 500 mLs. The consideration of intraoperative cell salvage for cases in whom large blood losses are expected will also be recommended based on clinical judgement. Some patients continue to lose blood from chest drains post-operatively, and a small proportion has major blood losses, which may require reoperation. Post-operative cell salvage could reduce RBC requirements, and/or improve post-operative haemoglobin concentration in patients, and may reduce other complications in patients who suffer major bleeding (for example: coagulopathy, hypothermia). These benefits may reduce complications, ICU and hospital length of stay, RBC and other blood product use, and HRQoL.</p>
Relevance to NICE guidance	<p>The NICE systematic review suggested that post-operative cell salvage may be clinically and cost-effective. However, the GDG recognised this was based on a small number of studies, and in patients in whom other recommended therapies, for example tranexamic acid, may not have been used.</p> <p>Post-operative salvage is available, but evidence to guide whether and when it should be used is weak.</p> <p>This question is of medium interest and it will inform the use of an available therapy and enable future updates to provide recommendations for this technology</p>
Relevance to the NHS	<p>If post-operative cell salvage is clinically and cost-effective, its implementation would benefit patients and the NHS, through reduced cost and reducing use of RBCs.</p> <p>Cardiac surgery is a costly and high volume procedure in the NHS.</p> <p>High quality evidence would enable business plans to be developed to support the introduction of post-operative cell salvage in an equitable manner to patients undergoing cardiac surgery</p>

National priorities	
Current evidence base	<p>The NICE systematic review found possible benefit from post-operative cell salvage, but problems with the evidence base were:</p> <ul style="list-style-type: none"> • The quality of the evidence was low • The evidence was not obtained in patient groups in whom other NICE guidance was implemented, namely the use of tranexamic acid, intraoperative cell salvage, and the use of restrictive transfusion triggers • The target population was not clearly defined
Equality	No
Feasibility	<p>This research is feasible within the NHS; the sample size is likely to be achievable within a high volume surgery, and there are no particular ethical issues.</p> <p>If post-operative cell salvage is shown to be cost-effective the cost of a trial is likely to be justified given the volume of this type of surgery each year. If a trial finds no benefit, it will provide high quality evidence that existing use of post-operative cell salvage should be reviewed.</p>
Other comments	It is likely that a manufacturer of post-operative cell salvage equipment would provide the excess treatment costs for a trial

1
2

Appendix P: Excluded clinical studies

P.1 Erythropoietin and iron

Study	Exclusion reason
Adamson 1996 ⁶	Systematic review: literature search not sufficiently rigorous. Systematic review: methods are not adequate/unclear
Andrews 1997 ¹⁹	Not review population. Non-anaemic patients
Atabek 1995 ²⁶	Incorrect study design
Beris 2008 ³⁷	Systematic review: study designs inappropriate
Bhandal 2006 ⁴¹	Non -surgical patients
Braga 1998 ⁵⁵	Letter to the editor
Breyman 1996 ⁵⁷	Includes patients with vaginal delivery and c-section.
Cherian 2013 ⁸⁸	Systematic review- checked references
Chua 2014 ⁹⁸	Abstract
Corwin 2002 ¹⁰⁹	Intensive care patients not about transfusion during surgery
Corwin 2004 ¹⁰⁷	Systematic review: study designs inappropriate
Corwin 2007 ¹⁰⁸	Intensive care patients. not about transfusion in surgery
Cuenca 2007 ¹¹⁴	Incorrect study design
Del campo 1982 ¹²³	Incorrect study design
Duh 2008 ¹³²	Systematic review is not relevant to review question or unclear PICO
Froessler 2012 ¹⁵⁴	Systematic review- checked references
Froessler 2013 ¹⁵³	Systematic review- checked references
Goodnough 1994 ¹⁷³	Incorrect population of interest- autologous blood donors
Jaspers 2014 ²²⁰	EPO after allogeneic haematopoietic cell transplantation
Jeong 2014 ²²¹	Incorrect study design
Krafft 2011 ²⁴⁷	Postpartum women. Mentions but does not stratify between spontaneous. caesarean and operative vaginal deliveries
Keating 2015 ²³³	Narrative review
Lee 2014 ²⁵⁶	Incorrect study design
Lin 2013 ²⁶⁶	Systematic review- checked references
Maclaren 2004 ²⁸¹	Systematic review is not relevant to review question or unclear PICO
Mercuriali 1994 ²⁹⁴	Incorrect population (autologous blood donation)
Monk 1999 ³⁰⁰	Inappropriate comparison. Incorrect interventions
Moonen 2008 ³⁰¹	Incorrect interventions
Mudge 2009 ³⁰⁹	Incorrect population of interest- kidney transplant patients
Mudge 2012 ³¹⁰	Incorrect population of interest- kidney transplant patients
Munoz 2006 ³¹⁵	Incorrect study design
Munoz 2008 ³¹³	Systematic review: study designs inappropriate; methods are not adequate/unclear
Pajoumand 2004 ³⁴³	Systematic review is not relevant to review question or unclear PICO
Pfeffer 2009 ³⁵⁴	No surgery patients
Pieracci 2009 ³⁵⁶	Intensive care patients. not about transfusion during surgery
Reim 2014 ³⁶⁸	Study protocol

Rowlands 2013 ³⁷⁶	Study protocol
Shimpo 1994 ³⁹⁵	In Japanese
Singh 2006 ⁴⁰⁰	No surgery patients
Sowade 1998 ⁴¹⁸	Systematic review is not relevant to review question or unclear PICO
Tran 2014 ⁴⁴⁹	Narrative review - checked references
Van loo 1996 ⁴⁶²	Incorrect population of interest- kidney transplant patients
Walpoth 1996 ⁴⁷³	Incorrect interventions
Watanabe 1992 ⁴⁸⁵	Autologous blood donation
Weber 2005 ⁴⁸⁸	Allogeneic and autologous blood transfusion. Unable to clearly separate results between autologous and allogeneic transfusions.
Yang 2011 ⁵⁰⁴	Systematic review: literature search not sufficiently rigorous
Yazicioglu 2001 ⁵⁰⁷	Incorrect population of interest- autologous blood donors

1 P.2 Alternatives

Study	Exclusion reason
Abdullah 2012 ⁴	Conference abstract
Adler ma 2011 ⁷	Incorrect interventions- systematic review
Aggarwal 2012 ⁸	Does not meet the inclusion criteria
Alipour 2013 ¹⁰	No outcomes of interest
Allanki 2009 ¹¹	Abstract
Almeida 2013 ¹²	Non-randomized prospective cohort study
Alshryda 2011 ¹⁴	Incorrect interventions- systematic review
Alshryda 2014 ¹⁵	Meta-analysis
Aluri 2012 ¹⁶	Abstract
Antinolfi 2010 ²⁰	Conference abstract
Antonopoulou 2013 ²¹	Abstract
Aoki 2012 ²³	Incorrect study design
Badeaux 2014 ²⁸	Systematic review of IV TXA in patients undergoing spine surgery. All references checked.
Baldus 2010 ³⁰	Incorrect study design
Barbara 2010 ³¹	Abstract
Basta 2012 ³²	Systematic review: methods are not adequate/unclear
Bhavana 2013 ⁴²	Abstract
Blatsoukas 2010 ⁴⁷	Not RCT
Boenigk 2011 ⁴⁸	Conference abstract
Borisov 2011 ⁵¹	Conference abstract
Bouali 2011 ⁵²	Conference abstract
Bracey 2009 ⁵³	Conference abstract
Briganti 2011 ⁵⁸	Conference abstract
Cacheux 2012 ⁶⁴	Conference abstract
Campbell 2012 ⁶⁷	Cell salvage plus heparin vs blood returned unprocessed

Cavolli 2011 ⁸¹	Abstract
Celebi 2006 ⁸²	Incorrect interventions
Chan 2013 ⁸³	Systematic review: methods are not adequate/unclear
Chen 2008 ⁸⁵	No relevant outcomes reported
Chen 2013 ⁸⁷	Systematic review: methods are not adequate/unclear
Chen 2013 ⁸⁶	Objective/outcomes of the study not relevant
Cheriyann 2013 ⁸⁹	Meta-analysis
Cholette 2011 ⁹²	Abstract
Cholette 2012 ⁹³	Abstract
Cholette 2013 ⁹⁴	Mean age of patients around 4 months
Christabel 2014 ⁹⁶	No relevant outcomes reported
Chu 2013 ⁹⁷	Non-randomised study
Crash-2 collaborators 2011 ¹⁰²	Population out of scope (trauma)
Dadure 2011 ¹¹⁶	Incorrect age group
Dalmau 2000 ¹¹⁷	Not review population
Damgaard 2010 ¹¹⁸	No relevant outcomes reported
Dhariwal 2014 ¹²⁷	Systematic review of use of ICS in caesarean section. Only one RCT was included in this review and this study is included in our evidence review.
Duran 2003 ¹³³	Not in English
Elgafy 2010 ¹³⁸	Systematic review: study designs inappropriate
Espahbod 2014 ¹³⁹	Meta-analysis
Faraoni 2011 ¹⁴³	Conference abstract
Faraoni 2012 ¹⁴⁵	Paediatric cardiac surgery - does not include all types of sur
Faraoni 2014 A ¹⁴⁴	Systematic review- does not meet our protocol criteria entirely
Fu 2013 ¹⁵⁵	Total knee arthroplasty - does not include all types of sur
Gandhi 2013 ¹⁵⁸	Total knee and hip arthroplasty -does not include all types of surgeries
Garg 2012 ¹⁵⁹	Conference abstract
Gautam 2011 ¹⁶⁰	Incorrect study design
Gautam 2013 ¹⁶¹	Systematic review: study designs inappropriate. Incorrect study design
Gill 2008 ¹⁶⁵	Spine surgery -no other surgeries included
Golab 2008 ¹⁶⁸	Incorrect age group
Gomez 2012 ¹⁷⁰	Conference abstract
Goobie 2011 ¹⁷¹	Incorrect age group
Gourlay 2013 ¹⁷⁷	Abstract
Goz 2013 ¹⁷⁸	Abstract
Grassin-delyle 2013 ¹⁷⁹	Incorrect interventions
Grundsell 1984 ¹⁸⁵	Does not meet inclusion criteria

Guay 2006 ¹⁸⁶	Incorrect age group
Gurusamy 2011 ¹⁸⁹	Incorrect population
Haien 2013 ¹⁹⁰	Systematic review: methods are not adequate/unclear
Halder 2013 ¹⁹¹	Incorrect study design
Hashimoto 2007 ¹⁹³	Cell salvage compared to autologous blood transfusion
Hassani 2012 ¹⁹⁴	Paper not in English
Hoelscher 2011 ²⁰¹	Conference abstract
Hogan 2014 ²⁰²	Abstract
Huang 2014 ²⁰⁶	Meta-analysis
Huet 1999 ²⁰⁷	Systematic review: methods are not adequate/unclear
Hutton 2012 ²⁰⁹	Conference abstract
Hutton 2012 ²⁰⁸	Systematic review: methods are not adequate/unclear
Ipema 2012 ²¹³	Systematic review: study designs inappropriate
Jahanshahi 2014 ²¹⁷	No outcomes of interest
Jairath 2014 ²¹⁸	Abstract
Jimenez-yuste 2002 ²²²	Incorrect interventions
Kashefi 2012 ²³⁰	Paper not in English
Kaste 1979 ²³¹	Use of TXA subarachnoid haemorrhage -not relevant population
Kelley 2014 ²³⁴	Retrospective case control study
Kim2014A ²⁴⁰	Systematic review
Klinck 1993 ²⁴¹	Conference abstract
Konig 2013 ²⁴⁵	Non-randomised study
Kristensen 1992 ²⁴⁸	Excluded from Cochrane review for insufficient data
Kumar 2014 ²⁴⁹	Systematic review- includes non-randomised studies
Leelahanon 2002 ²⁵⁹	Conference abstract
Li 2013 ²⁶³	Meta-analysis
Li 2014 ²⁶²	Meta-analysis of autologous blood transfusion drainage vs. no drainage in patients undergoing primary THA. All references checked.
Lian 2011 ²⁶⁴	Not in English
Lin 2011 ²⁶⁸	Incorrect study design
Liu 2010 ²⁶⁹	Not in English
Lundin 2013 ²⁷⁵	Abstract
Ma 2010 ²⁷⁹	Abstract
Macgillivray 2011 ²⁸⁰	Inappropriate comparison
Maniar 2012 ²⁸⁴	Control group not part of randomisation
Markar 2012 ²⁸⁵	Systematic review: methods are not adequate/unclear
Martinez-sanz 2011 ²⁸⁷	Conference abstract
Mason 2011 ²⁸⁹	Incorrect study design
Matkovic 2010 ²⁹⁰	Abstract

Meybohm 2013 ²⁹⁶	Systematic review: study designs inappropriate
Miao 2014 ²⁹⁷	Single-center, retrospective study
Moguilevitch 2011 ²⁹⁸	Abstract
Molloy 2007 ²⁹⁹	Incorrect interventions
Moore 2011 ³⁰²	Abstract
Morales 2013 ³⁰³	Abstract
Moret 2006 ³⁰⁴	Conference abstract
Morgenschweis 2011 ³⁰⁶	Abstract
Munoz 2013 ³¹⁶	Retrospective review
Munoz 2014 ³¹⁴	Before and after cohort study
Ngaage 2010 ³²⁶	Systematic review: study designs inappropriate. Incorrect interventions
Nicolai 2004 ³²⁸	Inappropriate comparison
Offierski 2013 ³³⁴	Conference abstract
Oishi 1997 ³³⁶	Inappropriate comparison
Ozal 2002 ³³⁹	Incorrect interventions
Panteli2013 ³⁴⁷	Systematic review- check references
Patel 2014 ³⁵¹	Incorrect interventions
Peitsidid 2014 ³⁵³	Systematic of TXA in patients with menorrhagia due to uterine fibroids (Incorrect population)
Proctor 2011 ³⁵⁷	Conference abstract
Prokopchuk-gauk 2012 ³⁵⁸	Conference abstract
Pundir 2013 ³⁵⁹	Systematic review
Risch 2000 ³⁷²	Not in English
Rybo 1972 ³⁷⁷	Not relevant surgery- conization
Sasanuma 2011 ³⁸¹	Incorrect interventions
Schouten 2009 ³⁸⁶	Inappropriate comparison
Shantikumar 2011 ³⁹¹	Systematic review: methods are not adequate/unclear
Shen 2013 ³⁹³	Abstract
Shimizu 2011 ³⁹⁴	Upto 40% of children in both groups less than 1 year of age
Shulman 1998 ³⁹⁷	Inappropriate comparison
Silva 2013 ³⁹⁸	Retrospective cross-sectional study
Sinclair 2009 ³⁹⁹	Systematic review: methods are not adequate/unclear
Singh 2010 ⁴⁰²	Incorrect study design
Song 2013 ⁴¹⁷	Craniosystosis -no other surgeries included
Song 2013 ⁴¹⁶	Orthognathic surgeries- other types of surgeries not included
So-Osman 2014 A ⁴¹³	Reports combined results for (ICS+PCS)+PCS as AUTO group; does not meet protocol
So-Osman 2014B ⁴¹⁰	Abstract
Specchiulli 2011 ⁴¹⁹	Conference abstract

Sukeik 2011 ⁴³²	Orthognathic surgery- not all surgeries included
Sun 2008 ⁴³³	Systematic review: methods are not adequate/unclear
Taj 2014 ⁴³⁴	No outcomes of interest
Tan2013 ⁴³⁵	Meta-analysis
Thomassen 2011 ⁴³⁹	Abstract
Toda 2013 ⁴⁴⁶	Conference abstract
Vacharaksa 2002 ⁴⁵⁸	Incorrect interventions
Vela 2012 ⁴⁶⁵	Conference abstract
Wang 2009 ⁴⁸⁰	Systematic review: methods are not adequate/unclear
Wardrop 2012 ⁴⁸²	Conference abstract
Washington 2009 ⁴⁸⁴	Abstract
Waters 2012 ⁴⁸⁷	Systematic review: methods are not adequate/unclear
Weltert 2013 ⁴⁹⁰	Inappropriate comparison
Williams 2009 ⁴⁹⁹	Abstract
Yagi 2012 ⁵⁰¹	Incorrect study design
Yang 2012 ⁵⁰⁵	Systematic review: methods are not adequate/unclear
Yang 2013 ⁵⁰²	Systematic review: methods are not adequate/unclear
Yassen 1993 ⁵⁰⁶	Not review population
Yutthakasemsunt2013 ⁵⁰⁹	Incorrect population- non-surgical patients with traumatic brain injury
Zaporozhan 2013 ⁵¹²	Conference abstract
Zhang 2012 ⁵¹³	Systematic review: methods are not adequate/unclear
Zhang 2014 ⁵¹⁴	Systematic review of TXA in patients undergoing TKA. Checked references.
Zhaohui 2014 ⁵¹⁶	Incorrect comparisons- TXA +epinephrine vs. Epinephrine
Zhaoyu 2014 ⁵¹⁵	Meta-analysis of TXA in patients undergoing primary TKA. All references checked.
Zheng 2000 ⁵¹⁷	Conference abstract
Zhou 2013 ⁵¹⁸	Systematic review: methods are not adequate/unclear
Zhu 2010 ⁵¹⁹	Conference abstract

1

2 P.3 Red blood cells RBC Targets

Study	Exclusion reason
Alvarez 2001 ¹⁷	Review article
Bellomo 2001 ³⁵	Abstract
Berns 2010 ³⁸	Incorrect study design. Narrative review
Bracey 1999 ⁵⁴	Incorrect interventions
Carson 1998 ⁷³	Narrative review
Carson 1998 ⁷⁴	Incorrect interventions. Inappropriate comparison

Carson 2002 ⁷⁷	Systematic review conducted in 2002 (all relevant references noted)
Carson 2011 ⁷⁸	Incorrect interventions
Carson 2012 ⁷⁶	clinical practice guideline
Carson 2013 ⁷⁵	Incorrect interventions
Colomo 2008 ¹⁰³	Incorrect interventions
De gast-bakker 2013 ¹²²	Incorrect interventions
Foss 2009 ¹⁵⁰	Incorrect interventions
Grover 2006 ¹⁸⁴	Incorrect interventions
Hardy 2003 ¹⁹²	Narrative review
Hebert 2000 ¹⁹⁶	Review article
Hogshire 2013 ²⁰³	Literature review
Holst 2013 ²⁰⁵	Incorrect interventions
Jairath 2013 ²¹⁹	Incorrect interventions
Johnson 1992 ²²⁴	Incorrect interventions
Karam 2011 ²²⁸	Incorrect interventions
Kennedy 2002 ²³⁵	Incorrect interventions
Lum 1997 ²⁷⁴	Incorrect study design
Napolitano 2004 ³²⁴	Narrative review
Nielsen 2012 ³²⁹	Incorrect interventions
O'hara 1999 ³³³	Review of medical records. Incorrect study design
Palmieri 2007 ³⁴⁴	Incorrect study design
Parker 2013 ³⁴⁸	Incorrect interventions
Rosland 2014 ³⁷³	Cohort study
Rouette 2010 ³⁷⁵	Incorrect interventions
Shehata 2012 ³⁹²	Incorrect interventions
Singh 2008 ⁴⁰¹	Incorrect study design. Critical review
So-osman 2010 ⁴¹¹	Incorrect interventions
So-osman 2013 ⁴¹²	Incorrect interventions
Strippoli giovanni 2006 ⁴³¹	Only includes patients with chronic kidney disease
Tay 2011 ⁴³⁶	Protocol for study
Valeri 1998 ⁴⁶¹	Article
Vichinsky 1995 ⁴⁶⁸	Patients with haemoglobinopathies
Viele 1994 ⁴⁶⁹	Literature review
Wali 2003 ⁴⁷²	Patients with haemoglobinopathies
Walsh 2013 ⁴⁷⁵	Incorrect interventions
Wang 2013 ⁴⁸¹	Includes only upper GI bleeding

Webert 2008 ⁴⁸⁹	Incorrect interventions
Whyte 2011 ⁴⁹³	Infants
Willems 2010 ⁴⁹⁷	Sub group analysis of cardiac surgery patients in TRIPICU study (Lacroix 2007 which has been included)

1 P.4 RBC Doses

Study	Exclusion reason
Arslan 2004 ²⁵	Incorrect interventions
Carson 2013 ⁷⁵	Incorrect interventions
Cooper 2011 ¹⁰⁵	Incorrect interventions
Lightdale 2012 ²⁶⁵	Incorrect study design
Parker 2013 ³⁴⁸	Incorrect interventions
Shehata 2012 ³⁹²	Incorrect interventions
Slight 2008 ⁴⁰⁶	Incorrect interventions
Smith 2013 ⁴⁰⁸	Review- checked references
Walsh 2013 ⁴⁷⁵	Incorrect interventions
Wang 2013 ⁴⁸¹	Incorrect interventions

2 P.5 Platelets

3 P.5.1 Platelet thresholds and targets

Study	Exclusion reason
Callow 2002 ⁶⁵	Incorrect study design
Cameron 2007 ⁶⁶	Incorrect study design
Goodnough 2002 ¹⁷²	Abstract
Hedde 2009 ¹⁹⁸	Incorrect interventions
Khan Assir 2013 ²³⁷	Incorrect interventions
Klump 1999 ²⁴³	Incorrect interventions
Nevo 2007 ³²⁵	Incorrect study design
Razzaghi 2012 ³⁶⁵	Only includes patients with upper GI bleeding
Rebulla 1996 ³⁶⁶	conference abstract
Sensebe 2005 ³⁸⁸	Incorrect interventions
Solomon 1978 ⁴¹⁵	Incorrect interventions
Stanworth 2004 ⁴²²	This Cochrane review has been updated in 2012
Tinmouth 2002 ⁴⁴³	Incorrect interventions
Tinmouth 2004 ⁴⁴⁴	Incorrect interventions
Wandt 1995 ⁴⁷⁷	Incorrect study design. conference abstract
Wandt 1998 ⁴⁷⁶	Incorrect study design
Wandt 2009 ⁴⁷⁸	conference abstract
Zahur-ur-rehman 2002 ⁵¹⁰	Incorrect interventions

1

2

Platelet targets

Study	Exclusion reason
Callow 2002 ⁶⁵	Incorrect interventions
Cameron 2007 ⁶⁶	Incorrect interventions
Diedrich 2005 ¹²⁸	Incorrect interventions
Estcourt 2012 ¹⁴¹	Incorrect interventions
Goodnough 2002 ¹⁷²	Incorrect interventions
Heckman 1997 ¹⁹⁷	Incorrect interventions
Heddle 2009 ¹⁹⁸	Incorrect interventions
Khan Assir 2013 ²³⁷	Incorrect interventions
Klumpp 1999 ²⁴³	Incorrect interventions
Nevo 2007 ³²⁵	Incorrect interventions
Razzaghi 2012 ³⁶⁵	Incorrect interventions
Rebulla 1996 ³⁶⁶	Incorrect interventions
Rebulla 1997 ³⁶⁷	Incorrect interventions
Sensebe 2005 ³⁸⁸	Incorrect interventions
Stanworth 2004 ⁴²²	Incorrect interventions
Stanworth 2010 ⁴²⁶	Incorrect interventions
Stanworth 2013 ⁴²⁷	Incorrect interventions
Tinmouth 2002 ⁴⁴³	Incorrect interventions
Tinmouth 2004 ⁴⁴⁴	Incorrect interventions
Wandt 1995 ⁴⁷⁷	Incorrect interventions
Wandt 1998 ⁴⁷⁶	Incorrect interventions
Wandt 2009 ⁴⁷⁸	Incorrect interventions
Wandt 2012 ⁴⁷⁹	Incorrect interventions
Zahur-ur-rehman 2002 ⁵¹⁰	Incorrect interventions
Zumberg 2002 ⁵²²	Incorrect interventions

3

P.5.2 Platelet doses

Study	Exclusion reason
Ackerman 2000 ⁵	Incorrect interventions
Cid 2007 ⁹⁹	Systematic review: methods are not adequate/unclear
Estcourt 2014 ¹⁴²	Protocol for Cochrane review
Herman 1995 ¹⁹⁹	Abstract
Josephson 2009 ²²⁵	Abstract
Kaufman 2015 ²³²	Secondary analysis of PLADO study. The study examined the frequency of transfusion related adverse events (TRAE) and whether the risk of TRAEs varied depending on the platelet characteristics.
Klumpp 1995 ²⁴²	Abstract
Klumpp 1999 ²⁴³	Crossover study
Lu 2011 ²⁷²	Abstract
Lu 2013 ²⁷³	Abstract

Murphy 2003 ³¹⁹	Inappropriate comparison. not randomised to compare platelet doses
Murphy 2006 ³²⁰	Inappropriate comparison. not randomised to compare platelet dose
Norol 1995 ³³¹	Abstract
Pedrazzoli 1997 ³⁵²	Abstract
Sahin 2013 ³⁷⁸	Abstract
Schiffer 1976 ³⁸³	Incorrect interventions
Schiffer 1976 ³⁸⁴	Incorrect interventions
Slichter 2005 ⁴⁰⁵	Incorrect interventions
Slichter 2006 ⁴⁰⁴	Narrative paper; background and rationale for PLADO trial
Slichter 2009 ⁴⁰³	Abstract
Stanworth 2004 ⁴²²	Systematic review; updated in 2012 (Estcourt 2012)
Steffens 2002 ⁴²⁹	Inappropriate comparison
Tinmouth 2002 ⁴⁴³	Abstract
Tinmouth 2003 ⁴⁴⁵	Systematic review: methods are not adequate/unclear
Triulzi 2009 ⁴⁵²	Abstract
Triulzi 2012 ⁴⁵³	Secondary analysis of Slichter 2010; outcomes not relevant to protocol
Van rhenen 2003 ⁴⁶³	Incorrect interventions
Wandt 2009 ⁴⁷⁸	Abstract

1 P.6 FFP

2 P.6.1 FFP thresholds and targets

Study	Exclusion reason
Casbard 2004 ⁷⁹	Systematic review is not relevant to review question or unclear PICO
Dara 2005 ¹¹⁹	Incorrect study design
Doussau 2014 ¹³⁰	Incorrect interventions
Levy 2011 ²⁶¹	Conference abstract
Muller 2011 ³¹²	Incorrect interventions
Stanworth 2004 ⁴²⁰	Systematic review is not relevant to review question or unclear PICO
Stanworth 2006 ⁴²¹	Narrative review
Stanworth 2007 ⁴²³	Systematic review is not relevant to review question or unclear PICO
Stanworth 2011 ⁴²⁴	Incorrect study design
Tinmouth 2008 ⁴⁴²	Conference abstract
Williamson 1999 ⁵⁰⁰	Incorrect interventions

3 P.6.2 FFP doses

Study	Exclusion reason
Abdel-wahab 2006 ³	Incorrect interventions
Anwar 2012 ²²	conference abstract

Besandre 2012 ⁴⁰	Conference abstract. Full paper not published so far.
Boldt 1989 ⁵⁰	Not in English
Carino 2009 ⁷¹	conference abstract
Casbard 2004 ⁷⁹	Systematic review is not relevant to review question or unclear PICO
Despotis 1994 ¹²⁶	Incorrect interventions
Dzik 2004 ¹³⁶	Narrative review
Khan 2007 ²³⁸	Incorrect interventions
Labarinas 2013 ²⁵¹	Literature review
Lauzier 2007 ²⁵⁴	Inappropriate comparison. Incorrect interventions
Lerner 2000 ²⁶⁰	Incorrect interventions
Levy 2011 ²⁶¹	Incorrect interventions. conference abstract
Matsumoto 2007 ²⁹¹	Incorrect interventions. Inappropriate comparison
Motta 2014 ³⁰⁸	Neonates
Muller 2011 ³¹²	Study protocol
Noddeland 2002 ³³⁰	Incorrect interventions. Inappropriate comparison
Puronen 2009 ³⁶⁰	Incorrect interventions. conference abstract
Sezik 2014 ³⁸⁹	Incorrect study design.
Stanworth 2004 ⁴²⁰	Not relevant comparisons. References noted. Incorrect interventions
Stanworth 2006 ⁴²¹	Literature review
Stanworth 2007 ⁴²³	Review article
Stanworth 2007 ⁴²⁵	Literature review
Tollofsrud 2003 ⁴⁴⁸	Inappropriate comparison. Incorrect interventions
Trimble 1964 ⁴⁵⁰	Incorrect interventions. Inappropriate comparison
Tripodi 2012 ⁴⁵¹	Incorrect study design
Urwyler 2009 ⁴⁵⁷	Study protocol
Vergheze 2008 ⁴⁶⁶	Narrative review
Walsh 2011 ⁴⁷⁴	Conference abstract. Study included
White 2011 ⁴⁹²	conference abstract
Willems 2014 ⁴⁹⁸	Incorrect interventions
Williamson 1999 ⁵⁰⁰	Incorrect interventions
Yang 2012 ⁵⁰³	Not all comparisons relevant. One study reference identified.
Youssef 2003 ⁵⁰⁸	Incorrect interventions. Inappropriate comparison

1 P.7 Cryoprecipitate

2 P.7.1 Cryoprecipitate thresholds and targets

Study	Exclusion reason
Abbott 2009 ²	Inappropriate comparison
Fenger-eriksen 2009 ¹⁴⁷	Incorrect interventions
French 2003 ¹⁵¹	Incorrect interventions. Inappropriate comparison
Galas 2012 ¹⁵⁶	Inappropriate comparison. conference abstract
Goldenberg 2006 ¹⁶⁹	Review article
Hesselvik 1987 ²⁰⁰	Not review population

Hwang 1991 ²¹¹	Not review population
Iyengar 2013 ²¹⁶	Incorrect interventions
Karlsson 2009 ²²⁹	Incorrect interventions
Ketchum 2006 ²³⁶	Review article
Koustousov 2012 ²⁴⁶	Incorrect interventions. conference abstract
Lang 1993 ²⁵²	Incorrect interventions. Inappropriate comparison
Lee 2014 ²⁵⁸	cohort study <1000 patients
Stevens 1986 ⁴³⁰	Not review population
Teitel 2011 ⁴³⁷	Incorrect interventions
Tinegate 2011 ⁴⁴¹	Survey
Warmuth 2012 ⁴⁸³	Systematic review is not relevant to review question or unclear PICO. Relevant papers ordered
Wikkelsø 2013 ⁴⁹⁶	Incorrect interventions
Zakout 2009 ⁵¹¹	conference abstract

1 P.7.2 Cryoprecipitate doses

Study	Exclusion reason
Abbott 2009 ²	Inappropriate comparison. Incorrect interventions
Fenger-eriksen 2009 ¹⁴⁷	Incorrect interventions
French 2003 ¹⁵¹	Incorrect interventions. Inappropriate comparison
Galas 2012 ¹⁵⁶	Incorrect interventions. Inappropriate comparison
Goldenberg 2006 ¹⁶⁹	Incorrect interventions. Inappropriate comparison
Hesselvik 1987 ²⁰⁰	Incorrect interventions. Inappropriate comparison
Holcomb 2013 ²⁰⁴	Incorrect interventions. Inappropriate comparison
Hwang 1991 ²¹¹	Incorrect interventions. Inappropriate comparison
Iyengar 2013 ²¹⁶	Incorrect interventions
Karlsson 2009 ²²⁹	Incorrect interventions
Ketchum 2006 ⁶⁶	Incorrect interventions
Koustousov 2012 ²⁴⁶	Incorrect interventions. Inappropriate comparison
Lang 1993 ²⁵²	Incorrect interventions. Inappropriate comparison
Lee 2014 ²⁵⁸	Incorrect interventions
Stevens 1986 ⁴³⁰	Incorrect interventions. Inappropriate comparison
Teitel 2011 ⁴³⁷	Inappropriate comparison. conference abstract
Warmuth 2012 ⁴⁸³	Incorrect interventions. Inappropriate comparison
Wikkelsø 2013 ⁴⁹⁶	Incorrect interventions. Inappropriate comparison

2 P.8 PCC

3 P.8.1 PCC thresholds and targets

Study	Exclusion reason
Arshad 2013 ²⁴	Protocol for study- for follow up
Awad 2013 ²⁷	Review
Bechtel 2011 ³³	Review. Not directly relevant to review question

Bershad 2010 ³⁹	Literature review
Cabral 2013 ⁶³	Retrospective case series review of 30 patients; not information on thresholds/targets
Chong 2010 ⁹⁵	Case series of 7 patients; evaluates PCC + FFP
Desmettre 2012 ¹²⁵	Paper not available
Eerenberg 2011 ¹³⁷	Healthy volunteer study; comparisons not relevant
Dowlatsahi 2012 ¹³¹	Canadian registry. n=141. Does not compare PCC transfusion at different thresholds/target levels
Huynh 2014 ²¹⁰	n=44. Small retrospective study
Johansen 2013 ²²³	Protocol for Cochrane review on PCC for peri-operative reversal of Vitamin K antagonist
Junagade 2007 ²²⁶	Abstract
Knight 2009 ²⁴⁴	Systematic review on efficacy of r FactorVIIa and aPCC
Leal-noval 2013 ²⁵⁵	Do not report number of patients in allocated to low (15 IU/kg) and high dose groups (25 IU/kg)
Lin 2013 ²⁶⁷	Systematic review of PCCs and fibrinogen concentrates (FIBCs) in combination
Lusher 1980 ²⁷⁸	RCT evaluating efficacy of 2 PCC preparations with placebo; does not evaluate INR thresholds or targets-wrong comparison
Lusher 1983 ²⁷⁷	Compares 2 different types of PCCs, not relevant comparison
Lusher 1984 ²⁷⁶	Narrative review of PCC and Factor VIII inhibitors
Mai 2013 ²⁸³	Abstract
Otite 2013 ³³⁸	Abstract
Pabinger 2008 ³⁴⁰	44 patients, no control arm, prospective study
Pabinger 2010 ³⁴¹	Evaluates impact of speed of PCC infusion
Patanwala 2011 ³⁵⁰	Systematic review- relevant papers ordered
Solbeck 2012 ⁴¹⁴	Systematic review- checked references
Staudinger 1999 ⁴²⁸	Cohort study, n=16.
Varga 2013 ⁴⁶⁴	Retrospective case series on efficacy of PCC dose; to include if RCTs included of every low quality/ do not provide helpful evidence; Info for other considerations
Valentino 2009 ⁴⁶⁰	Abstract
Voils 2012 ⁴⁷¹	Systematic review- relevant references noted

1 P.8.2 PCC doses

Study	Exclusion reason
Bershad 2010 ³⁹	Literature review
Cabral 2013 ⁶³	No comparison groups
Chong 2010 ⁹⁵	Case series of 7 patients; evaluates PCC + FFP
Desmettre 2012 ¹²⁵	Paper not available
Eerenberg 2011 ¹³⁷	Healthy volunteer study; comparisons not relevant
Huynh 2014 ²¹⁰	Small retrospective study, n=44.
Knight 2009 ²⁴⁴	Systematic review on efficacy of Factor VII and PCC

Leal-Noval 2013 ²⁵⁵	Does not report number of patients in allocated to low (15 IU/kg) and high dose groups (25 IU/kg)
Lusher 1980 ²⁷⁸	RCT evaluating efficacy of 2 PCC preparations with placebo; dose not evaluate INR thresholds or targets-wrong comparison
Lusher 1983 ²⁷⁷	Compares 2 different types of PCCs, not relevant comparison
Lusher 1984 ²⁷⁶	Narrative review of PCC and Factor VIII inhibitors
Pabinger 2008 ³⁴⁰	Does not report outcomes/results according to the different doses of PCC
Pabinger 2010 ³⁴¹	Evaluates impact of speed of PCC infusion
Varga 2013 ⁴⁶⁴	Retrospective case series on efficacy of PCC dose

1 P.9 Monitoring for acute reactions

2 None

3 P.10 Electronic decision support

Reference	Reason for exclusion
Choi 2014 ⁹¹	Abstract
Cotterell 2013 ¹¹⁰	Systematic review
Estcourt 2013 ¹⁴⁰	Abstract
Goodnough 2013 ¹⁷⁴	Abstract
Rao 2013 ³⁶³	Abstract
Morris 2011 ³⁰⁷	Abstract
Mascotti 2009 ²⁸⁸	Abstract
Kuo 2011 ²⁵⁰	Abstract
Gregurek 2010 ¹⁸²	Abstract
Gregurek 2009 ¹⁸¹	Abstract
Goddard 2010 ¹⁶⁷	Abstract
Rothschild 2004 ³⁷⁴	Abstract
Uriz 2011 ⁴⁵⁶	Intervention does not match protocol (for patient identification)
Alves 2002 ¹⁸	Population does not match protocol (In neonates)
Schnurr 2010 ³⁸⁵	Intervention does not match protocol
Febra 2011 ¹⁴⁶	Abstract
Guerra 2010 ¹⁸⁷	Abstract
Martinez 2011 ²⁸⁶	Abstract
McCroy 2010 ²⁹³	Abstract
Waters 2012 ⁴⁸⁶	Abstract
Zijlker 2013 ⁵²⁰	Abstract
Shojania 2009 ³⁹⁶	Review (not relevant comparisons)
Philcox 1987 ³⁵⁵	Inocorrect intervention
Palo 2006 ³⁴⁵	Intervention does not match protocol(database system to manage blood component use in hospital)
Morgan 1973 ³⁰⁵	Intervention does not match protocol(computer controlled automated transfusion, not for decision support)

1 P.11 Electronic patient identification

Study	Exclusion reason
Aandahl 2007 ¹	Incorrect interventions. Narrative review
Baele 1994 ²⁹	Incorrect interventions
Brewer 1977 ⁵⁶	Incorrect interventions. Narrative paper
Burrows 2009 ⁶⁰	Incorrect interventions. Evaluates inaccessibility of identification bands in operating theatre
Clark 1984 ¹⁰⁰	Narrative paper
Clifford 2013 ¹⁰¹	Incorrect interventions
Cottrell 2013 ¹¹⁰	Audit of transfusion practice. Incorrect interventions
Davis 2012 ¹²¹	Incorrect interventions
Dzik 2003 ¹³⁵	Review
Dzik 2007 ¹³⁴	Narrative paper
Finlay 2005 ¹⁴⁸	Incorrect interventions
Galusha 2003 ¹⁵⁷	Narrative paper
Goodnough 2009 ¹⁷⁶	Incorrect interventions
Goodnough 2012 ¹⁷⁵	Incorrect interventions. Narrative paper
Green 2008 ¹⁸⁰	Inappropriate comparison. Narrative paper
Grimm 2010 ¹⁸³	Inappropriate comparison. Survey; no co-relation presented between patient identification by electronic methods and inappropriate transfusions
Gumpeni 2006 ¹⁸⁸	Narrative paper
Ibojie 2000 ²¹²	Incorrect interventions
Mercuriali 1996 ²⁹⁵	Incorrect interventions (only non-electronic patient identification)
Murphy 2007 ³¹⁸	Incorrect interventions
Novis 2003 ³³²	Incorrect interventions
Ohsaka 2009 ³³⁵	Incorrect interventions
Pagliari 2006 ³⁴²	narrative review
Quillen 2006 ³⁶¹	Incorrect interventions
Renner 1993 ³⁶⁹	Incorrect interventions
Rentas 1999 ³⁷⁰	Incorrect interventions
Sandler 2007 ³⁷⁹	Wrong comparison (only evaluates if RFID system can be implemented, does not evaluate prevention of errors)
Schulmeister 2008 ³⁸⁷	Narrative paper
Smith 2011 ⁴⁰⁹	Incorrect interventions
Thomas 2004 ⁴³⁸	Incorrect interventions. Narrative paper
Tiehen 1998 ⁴⁴⁰	Narrative paper
Valenstein 2004 ⁴⁵⁹	Review, not systematic
Wenz 1991 ⁴⁹¹	Incorrect interventions (only non-electronic patient identification)
Wickham 2006 ⁴⁹⁵	Inappropriate comparison
Wickham 2006 ⁴⁹⁴	Abstract

2 P.12 Patient information

Reference	Reason for exclusion
Benson 1996 ³⁶	Evaluates patients views regarding receiving home transfusions

Reference	Reason for exclusion
Bielby 2013 ⁴³	Abstract
Bishop 2009 ⁴⁵	Abstract
Bishop 2010 ⁴⁶	Does not address review question; no information on patients views regarding info
Burgess 2006 ⁵⁹	Audit results and recommendations for practice
Busby 2012 ⁶²	Abstract
Busby 2013 ⁶¹	Abstract
Cankovic 2009 ⁶⁹	Abstract
Cankovic 2011 ⁷⁰	Abstract
Carruther 2001 ⁷²	Audit and survey of hospital practices regarding consent; patients views not reported
Cassidy 2013 ⁸⁰	Abstract
Cong 2009 ¹⁰⁴	Abstract
Corkery2013 ¹⁰⁶	Abstract
Court2010 ¹¹²	Abstract
Court2012 ¹¹¹	Abstract
Davis2012 ¹²¹	Survey to assess patients willingness to participate in transfusion related behaviours related to identity checking and administration of blood
Friedman2011 ¹⁵²	Abstract
Islam2011 ²¹⁵	Abstract
Khan2012 ²³⁹	Evaluates use of a clinician tool to aid patient counselling before blood transfusion
Latreille2010 ²⁵³	Abstract
Lee2003 ²⁵⁷	Evaluates people's perception of the risk of blood transfusion in comparison to other hazards (for example, pesticides, caffeine); wrong objective
Lowe2001 ²⁷⁰	Evaluates perception of risk of blood transfusion with respect to receiving own blood/blood substitutes
Mahapatra2013 ²⁸²	Abstract
Mccarthy2001 ²⁹²	Abstract
Muhammad2014 ³¹¹	Abstract
Naim2011a ³²³	Abstract
Naim2011b ³²²	Abstract
Naim2012 ³²¹	Abstract
Ngo2013 ³²⁷	Qualitative Systematic review
Orme2013 ³³⁷	Evaluates experiences of patients' experience of living with anaemia and receiving transfusion at a day hospice; does not look at what information people want
Tolich2010 ⁴⁴⁷	Abstract
Twiss2011 ⁴⁵⁵	Abstract
Vetter2014 ⁴⁶⁷	Survey of patients perception of risk of blood transfusion and associated patients characteristics; no reporting of what info people may want

1

2 **P.12.1 RBC Thresholds**

Study	Exclusion reason
Carson 2012 ⁷⁶	Clinical practice guideline
Chatterjee 2013 ⁸⁴	Systematic review: literature search not sufficiently rigorous
Chirico 2011 ⁹⁰	Pre-term infants
Curley 2014 ¹¹⁵	Systematic review- checked references
Desjardins 2012 ¹²⁴	Systematic review: study designs inappropriate
Fischer 2010 ¹⁴⁹	Incorrect interventions
Gauvin 2010 ¹⁶²	Analytic cohort analysis
Hearnshaw 2010 ¹⁹⁵	Incorrect study design
Holst 2013 ²⁰⁵	Protocol- TRISS trial
Jairath 2013 ²¹⁹	Protocol
Kahan 2013 ²²⁷	Statistical analysis plan- TRIGGER trial
Lightdale 2012 ²⁶⁵	Incorrect study design
Parker 2013 ³⁴⁸	Incorrect interventions. Inappropriate comparison
Parker 2014 ³⁴⁹	Systematic review- checked references
Rouette 2010 ³⁷⁵	Sub group analysis of surgery patients in TRIPICU study- we are only updating the Cochrane review (that is, including studies after 2011)
Shah 2015 ³⁹⁰	Review article
So-Osman 2010 ⁴¹¹	Incorrect interventions
So-Osman 2013 ⁴¹²	Post-hoc analysis
Tay 2011 ⁴³⁶	Protocol -TRIST trial
Wang 2013 ⁴⁸¹	Includes only upper GI bleeding
Whyte 2011 ⁴⁹³	Low birth-weight infants
Willems 2010 ⁴⁹⁷	Sub group analysis of cardiac surgery patients in TRIPICU study (Lacroix 2007 which has been included)

3

4 **Appendix Q: Excluded economic studies**

5 **Q.1 Erythropoietin and iron**

Reference	Reason for exclusion
Bedair 2015 ³⁴	This US within trial (prospective cohort) cost consequence analysis of erythropoietin was assessed as partially applicable with potentially serious limitations. The GDG judged the three cost utility analyses (two UK and one USA) and one German cost consequence analysis, were of greater applicability and methodological quality, and therefore this study was selectively excluded.

6 **Q.2 Alternatives to blood transfusion**

Reference	Reason for exclusion
Murphy 2005 ³¹⁷	This UK cost-consequence analysis of cell salvage was assessed as partially applicable with potentially serious limitations. However, the GDG

Reference	Reason for exclusion
	judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Crotty 2006 ¹¹³	This UK cost–comparison of cell salvage was assessed as partially applicable with very serious limitations. The GDG judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Savvidou 2009 ³⁸²	This Greek cost–consequence analysis of cell salvage was assessed as partially applicable with potentially limitations. The GDG judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Boese 2011 ⁴⁹	This US cost–consequence analysis of cell salvage was assessed as partially applicable with very serious limitations. The GDG judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Dobosz 2012 ¹²⁹	This Polish cost–consequence analysis of cell salvage was assessed as partially applicable with potentially limitations. The GDG judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Rao 2012 ³⁶⁴	This US cost–comparison of cell salvage was assessed as partially applicable with very serious limitations. The GDG judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Canan 2013 ⁶⁸	This US cost–utility analysis of cell salvage was assessed as not applicable with very serious limitations: QALYs estimated from expert opinion, time frame and discounting unclear, patient perspective taken, and very high unit cost of allogeneic blood which is not representative of current UK unit costs. Therefore this study was excluded.
Munoz 2013 ³¹⁶	This Spanish cost–consequence analysis of cell salvage was assessed as partially applicable with potentially limitations. The GDG judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Albright 2014 ⁹	This US comparative cost analysis of cell salvage was assessed as partially applicable and with potentially serious limitations. The GDG judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Bilgili 2014 ⁴⁴	This Turkish cost–consequence analysis of cell salvage was assessed as partially applicable with very serious limitations. Health outcome not expressed as QALYs. No information provided on how the total costs were estimated. Effectiveness data from a retrospective study and therefore not included in the clinical review. Therefore this study was excluded.
Munoz 2014 ³¹⁴	This Spanish cost–consequence analysis of cell salvage was assessed as partially applicable with potentially limitations. The GDG judged that the available UK cost–utility analysis ¹²⁰ was of greater applicability and methodological quality, and therefore this study was selectively excluded.
Lozano 2008 ²⁷¹	This Spanish within trial (retrospective observational) cost consequence analysis of tranexamic acid was assessed as partially applicable with potentially serious limitations. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.

Reference	Reason for exclusion
Gill 2009 ¹⁶⁴	This US within trial (RCT) cost consequence analysis of tranexamic acid was assessed as partially applicable with potentially serious limitations. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.
Irisson 2012 ²¹⁴	This French within trial (retrospective cohort) cost consequence analysis of tranexamic acid was assessed as partially applicable with potentially serious limitations. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.
Panchmatia 2012 ³⁴⁶	This UK within trial (prospective cohort) cost consequence analysis of tranexamic acid was assessed as partially applicable with potentially serious limitations. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.
Gillette 2013 ¹⁶⁶	This US within trial (retrospective cohort) cost consequence analysis of tranexamic acid was assessed as partially applicable with potentially serious limitations. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.
Slover 2014 ⁴⁰⁷	This US cost-effectiveness analysis (decision tree) was assessed as partially applicable with very serious limitations. Relative treatment effects were not reported or referenced in this analysis. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.
Vigna-Taglianti 2014 ⁴⁷⁰	This Italian within trial (before and after study with regression analysis) cost consequence analysis of tranexamic acid was assessed as partially applicable with potentially serious limitations. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.
Tuttle 2014 ⁴⁵⁴	This US within trial (retrospective cohort) cost consequence analysis of tranexamic acid was assessed as partially applicable with potentially serious limitations. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.
George 2015 ¹⁶³	This UK within trial (retrospective cohort) cost consequence analysis of tranexamic acid was assessed as partially applicable with potentially serious limitations. This study was selectively excluded as it was superseded by two recent UK cost consequence analyses ^{13,362} , both of which were within-trial analyses of RCTs that are included in clinical review and therefore more applicable to the UK NHS context.

1 Q.3 Red blood cells

Reference	Reason for exclusion
-----------	----------------------

Reference	Reason for exclusion
Palmieri 2007 ³⁴⁴	This study was assessed as partially applicable with very serious limitations. Based on a before and after study that was excluded from the clinical review. Savings are a product of blood usage and cost of a unit of blood (US cost). Therefore this study was excluded.
Zilberberg 2007 ⁵²¹	This study was assessed as partially applicable with very serious limitations. Savings are a product of blood usage and cost of a unit of blood (US cost). Therefore this study was excluded.

1 Q.4 Platelets

2 Q.4.1 Platelet thresholds and targets

Reference	Reason for exclusion
Sarode 2010 ³⁸⁰	This study was assessed as partially applicable with very serious limitations. Based on a before and after study that was excluded from the clinical review protocol. Not all costs are included and source of unit costs unclear (appears to be based on a US hospital). Therefore this study was excluded.

3 Q.4.2 Platelet dose

Reference	Reason for exclusion
Riley 2012 ³⁷¹	This study was assessed as partially applicable with very serious limitations. Based on platelet doses that are not UK standard doses. Assumes same health outcomes for all doses and unit costs are from a US perspective. Therefore this study was excluded.

4 Q.5 Fresh frozen plasma

5 Q.5.1 Fresh frozen plasma thresholds and targets

Reference	Reason for exclusion
Sarode 2010 ³⁸⁰	This study was assessed as partially applicable with very serious limitations. Based on a before and after study that was excluded from the clinical review protocol. Not all costs are included and source of unit costs unclear (appears to be based on a US hospital). Therefore this study was excluded.

6

Appendix R: NICE technical team

Name	Role
Sharon Summers-Ma	Guideline Lead
Martin Allaby	Clinical Advisor
Beth Shaw	Technical Lead
Bhash Naidoo	Health Economist
Louise Shires	Guideline Commissioning Manager
Joy Carvill	Guideline Coordinator
James Hall	Editor

References

- 1
- 2
- 3 1 Aandahl GS, Knutsen TR, Nafstad K. Implementation of ISBT 128, a quality system, a
4 standardized bar code labeling of blood products worldwide, electronic transfusion pathway:
5 four years of experience in Norway. *Transfusion*. 2007; 47(9):1674-1678
- 6 2 Abbott LS, Deevska M, Fernandez CV, Dix D, Price VE, Wang H et al. The impact of prophylactic
7 fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system
8 thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving
9 asparaginase. *Blood*. 2009; 114(25):5146-5151
- 10 3 Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin
11 time and bleeding in patients with mild coagulation abnormalities. *Transfusion*. 2006;
12 46(8):1279-1285
- 13 4 Abdullah A, Javed A. Does topical tranexamic acid reduce post-turp hematuria: A double blind
14 randomized control trial. *Urology*. 2012; 80(3 Suppl 1):S221-S222
- 15 5 Ackerman SJ, Klumpp TR, Guzman GI, Herman JH, Gaughan JP, Bleecker GC et al. Economic
16 consequences of alterations in platelet transfusion dose: analysis of a prospective,
17 randomized, double-blind trial. *Transfusion*. 2000; 40(12):1457-1462
- 18 6 Adamson J. Perisurgical use of epoetin alfa in orthopedic surgery patients. *Seminars in
19 Hematology*. 1996; 33(2 Suppl 2):55-59
- 20 7 Adler Ma SC, Brindle W, Burton G, Gallacher S, Hong FC, Manelius I et al. Tranexamic acid is
21 associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a
22 systematic review and meta-analysis. *Journal of Cardiothoracic and Vascular Anesthesia*.
23 2011; 25(1):26-35
- 24 8 Aggarwal V, Kapoor PM, Choudhury M, Kiran U, Chowdhury U. Utility of Sonoclot analysis and
25 tranexamic acid in tetralogy of Fallot patients undergoing intracardiac repair. *Annals of
26 Cardiac Anaesthesia*. 2012; 15(1):26-31
- 27 9 Albright CM, Rouse DJ, Werner EF. Cost savings of red cell salvage during cesarean delivery.
28 *Obstetrics and Gynecology*. 2014; 124(4):690-696
- 29 10 Alipour M, Tabari M, Keramati M, Zarmehri AM, Makhmalbaf H. Effectiveness of oral
30 tranexamic acid administration on blood loss after knee arthroplasty: a randomized clinical
31 trial. *Transfusion and Apheresis Science*. 2013; 49(3):574-577
- 32 11 Allanki S. Transfusion alternatives in liver transplantation: single center study. *Vox Sanguinis*.
33 2009; 96:242
- 34 12 Almeida RM, Leitao L. The use of cell saver system in cardiac surgery with cardiopulmonary
35 bypass. *Revista Brasileira De Cirurgia Cardiovascular*. 2013; 28(1):76-82
- 36 13 Alshryda S, Mason J, Sarda P, Nargol A, Cooke N, Ahmad H et al. Topical (intra-articular)
37 tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a
38 randomized controlled trial (TRANX-H). *Journal of Bone and Joint Surgery American Volume*.
39 2013; 95(21):1969-1974

- 1 14 Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total
2 knee replacement: a systematic review and meta-analysis. *Journal of Bone and Joint Surgery*
3 *British Volume*. 2011; 93(12):1577-1585
- 4 15 Alshryda S, Sukeik M, Sarda P, Blenkinsopp J, Haddad FS, Mason JM. A systematic review and
5 meta-analysis of the topical administration of tranexamic acid in total hip and knee
6 replacement. *Bone and Joint Journal*. 2014; 96 B(8):1005-1015
- 7 16 Aluri S, Wrench IJ, Wilson M. Cell salvage during caesarean section reduces perioperative
8 allogeneic red cell transfusion in suitable patients. *International Journal of Obstetric*
9 *Anesthesia*. 2012; 21:S17
- 10 17 Alvarez G, Hebert PC, Szick S. Debate: transfusing to normal haemoglobin levels will not
11 improve outcome. *Critical Care*. 2001; 5(2):56-63
- 12 18 Alves-Dunkerson JA, Hilsenrath PE, Cress GA, Widness JA. Cost analysis of a neonatal point-of-
13 care monitor. *American Journal of Clinical Pathology*. 2002; 117(5):809-818
- 14 19 Andrews CM, Lane DW, Bradley JG. Iron pre-load for major joint replacement. *Transfusion*
15 *Medicine*. 1997; 7(4):281-286
- 16 20 Antinolfi P, Innocenti B, Caraffa A, Cerulli G. Blood loss in total knee arthroplasty: Mechanical
17 vs pharmacological approach. *European Surgical Research*. 2010; 45(3-4):293
- 18 21 Antonopoulou E, Digas G, Meletiadis G, Koutsogiannis I, Netzadin N, Tanasidis A et al. The
19 effectiveness of tranexamic acid in total knee replacement. *Regional Anesthesia and Pain*
20 *Medicine*. 2013; 38(5 Suppl 1):E177
- 21 22 Anwar F, Mahmoud Y, Merenkov ZA, Mohd FA, Al Malki A. Auditing ffp usage: Using pre and
22 post coagulation testing as a tool. *Vox Sanguinis*. 2012; 103:76
- 23 23 Aoki M, Okawa Y, Goto Y, Ogawa S, Baba H. Local administration of tranexamic acid in off-
24 pump coronary artery bypass. *Asian Cardiovascular and Thoracic Annals*. 2012; 20(6):658-662
- 25 24 Arshad F, Ickx B, Beem RT, Polak W, Grüne F, Nevens F et al. Prothrombin complex
26 concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-
27 trial. *BMC Surgery*. 2013; 13:22
- 28 25 Arslan O, Toprak S, Arat M, Kayalak Y. Hb content-based transfusion policy successfully
29 reduces the number of RBC units transfused. *Transfusion*. 2004; 44(4):485-488
- 30 26 Atabek U, Alvarez R, Pello MJ, Alexander JB, Camishion RC, Curry C et al. Erythropoetin
31 accelerates hematocrit recovery in post-surgical anemia. *American Surgeon*. 1995; 61(1):74-
32 77
- 33 27 Awad NI, Cocchio C. Activated prothrombin complex concentrates for the reversal of
34 anticoagulant-associated coagulopathy. *P and T*. 2013; 38(11):696-701
- 35 28 Badaeux J, Hawley D. A systematic review of the effectiveness of intravenous tranexamic Acid
36 administration in managing perioperative blood loss in patients undergoing spine surgery.
37 *Journal of Perianesthesia Nursing*. 2014; 29(6):459-465

- 1 29 Baele PL, De Bruyere M, Deneys V, Dupont E, Flament J, Lambermont M et al. Bedside
2 transfusion errors. A prospective survey by the Belgium SANGUIS Group. *Vox Sanguinis*. 1994;
3 66(2):117-121
- 4 30 Baldus CR, Bridwell KH, Lenke LG, Okubadejo GO. Can we safely reduce blood loss during
5 lumbar pedicle subtraction osteotomy procedures using tranexamic acid or aprotinin? A
6 comparative study with controls. *Spine*. 2010; 35(2):235-239
- 7 31 Barbara E, Di Spigno N, Perazzo P, Scardino M. A new concept in the post-operative
8 autologous blood reinfusion in orthopaedic surgery. *Regional Anesthesia and Pain Medicine*.
9 2010; 35(5):E67
- 10 32 Basta MN, Stricker PA, Taylor JA. A systematic review of the use of antifibrinolytic agents in
11 pediatric surgery and implications for craniofacial use. *Pediatric Surgery International*. 2012;
12 28(11):1059-1069
- 13 33 Bechtel BF, Nunez TC, Lyon JA, Cotton BA, Barrett TW. Treatments for reversing warfarin
14 anticoagulation in patients with acute intracranial hemorrhage: a structured literature review.
15 *International Journal of Emergency Medicine*. 2011; 4(1):40
- 16 34 Bedair H, Yang J, Dwyer MK, McCarthy JC. Preoperative erythropoietin alpha reduces
17 postoperative transfusions in THA and TKA but may not be cost-effective. *Clinical*
18 *Orthopaedics and Related Research*. 2015; 473:590-596
- 19 35 Bellomo R. Will less liberal red-cell transfusion (with a lower haemoglobin threshold) still
20 reduce rates of death and organ failure? *Medical Journal of Australia*. 2001; 175(7):387
- 21 36 Benson K, Balducci L, Milo KM, Heckel L, Lyman GH. Patients' attitudes regarding out-of-
22 hospital blood transfusion. *Transfusion*. 1996; 36(2):140-143
- 23 37 Beris P, Munoz M, Garcia-Erce JA, Thomas D, Maniatis A, Van der Linden P. Perioperative
24 anaemia management: consensus statement on the role of intravenous iron. *British Journal of*
25 *Anaesthesia*. 2008; 100(5):599-604
- 26 38 Berns JS. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp
27 Therapy study for anemia management in dialysis patients? *Current Opinion in Nephrology*
28 *and Hypertension*. 2010; 19(6):567-572
- 29 39 Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-
30 related intracranial hemorrhage: a review of the literature. *Neurocritical Care*. 2010;
31 12(3):403-413
- 32 40 Besandre R, Soundar EP, Hartman SK, Teruya J, Hui SR. The incidence and effectiveness of
33 plasma transfusion in correcting mild coagulopathy. *Transfusion*. 2012; 52:113A-114A
- 34 41 Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. *BJOG: An*
35 *International Journal of Obstetrics and Gynaecology*. 2006; 113(11):1248-1252
- 36 42 Bhavana G, Mittal S. Evaluation of efficacy of prophylactic injection tranexamic acid in
37 decreasing blood loss before and after caesarean section. *BJOG: An International Journal of*
38 *Obstetrics and Gynaecology*. 2013; 120:32
- 39 43 Bielby LJ, Stevenson L, Perillo J, Glazebrook B, Beard P, Hennessy C et al. Consent for blood
40 transfusion-are we informing patients? *Vox Sanguinis*. 2013; 105:82

- 1 44 Bilgili MG, Ercin E, Peker G, Kural C, Basaran SH, Duramaz A et al. Efficiency and cost analysis
2 of cell saver auto transfusion system in total knee arthroplasty. *Balkan Medical Journal*. 2014;
3 31(2):149-153
- 4 45 Bishop L. Controversies in anaemia: Making blood transfusion decisions. *European Journal of*
5 *Cancer, Supplement*. 2009; 7(2-3):47
- 6 46 Bishop L, Faithfull S, Allan H. An exploration of the influences on clinical decision making and
7 the culture of blood transfusion practise in cancer-related anaemia using an ethnographic
8 methodology. *Supportive Care in Cancer*. 2010; 19(2):203-210
- 9 47 Blatsoukas KS, Drosos GI, Kazakos K, Papaioakim M, Gioka T, Chloropoulou P et al. Prospective
10 comparative study of two different autotransfusion methods versus control group in total
11 knee replacement. *Archives of Orthopaedic and Trauma Surgery*. 2010; 130(6):733-737
- 12 48 Boenigk K, Verma K, Hoelscher C, Huncke KT, Lonner B, Errico T. The efficacy of antifibrinoly
13 tics at reducing blood loss in major spine surgery: A prospective randomized comparison of
14 tranexamic acid, aminocaproic acid, and placebo. *European Journal of Anaesthesiology*. 2011;
15 28:90
- 16 49 Boese CK, Gallo TJ, Weis M, Baker R, Plantikow CJ, Cooley B. Efficacy and cost-effectiveness of
17 a blood salvage system in primary total knee arthroplasty: a retrospective match-controlled
18 chart review. *Iowa Orthopaedic Journal*. United States 2011; 31:78-82
- 19 50 Boldt J, Kling D, von Bormann B, Zuge M, Hempelmann G. Homologous fresh frozen plasma in
20 heart surgery. Myth or necessity. *Der Anaesthesist*. 1989; 38(7):353-359
- 21 51 Borisov D, Yudin S, Krylov O, Markov B, Istomina N. Tranexamic acid in hip arthroplasty: a
22 dose-response study. *European Journal of Anaesthesiology*. 2011; 28:88
- 23 52 Bouali Y, Rais K, Belhaj H, Jabri H, Kaabachi O. Continuous vs. repeated bolus of tranexamic
24 acid for total knee arthroplasty. *European Journal of Anaesthesiology*. 2011; 28:89-90
- 25 53 Bracey A, Allison PM, Giesecke NM, Reul RM, Radovancevic R. Evaluation of automated
26 autotransfusion system in cardiovascular surgery. *Transfusion*. 2009; 49:168A
- 27 54 Bracey AW, Radovancevic R, Riggs SA, Houston S, Cozart H, Vaughn WK et al. Lowering the
28 hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient
29 outcome. *Transfusion*. 1999; 39(10):1070-1077
- 30 55 Braga M. Randomized multicentre trial of the influence of recombinant human erythropoietin
31 on intraoperative and postoperative transfusion need in anaemic patients undergoing right
32 hemicolectomy for carcinoma. *British Journal of Surgery*. 1998; 85(9):1306-1307
- 33 56 Brewer MK, Bass G, Wenk RE. Mechanical random access of blood bank records. *Journal of*
34 *Medical Systems*. 1977; 1(3):275-282
- 35 57 Breyman C, Zimmermann R, Huch R, Huch A. Use of recombinant human erythropoietin in
36 combination with parenteral iron in the treatment of postpartum anaemia. *European Journal*
37 *of Clinical Investigation*. 1996; 26(2):123-130
- 38 58 Briganti A, Landoni G, Salonia A, Bertarelli G, Bianchi M, Tutolo M et al. Effectiveness of short-
39 term tranexamic acid in reducing bleeding and transfusion rate in patients undergoing radical

- 1 retropubic prostatectomy: Results of a prospective, randomized, double-blind controlled trial.
2 European Urology, Supplements. 2011; 10(2):282
- 3 59 Burgess R. Blood transfusion in A&E. Emergency Nurse. 2006; 13(10):18-22
- 4 60 Burrows JM, Callum JL, Belo S, Etchells E, Leeksa A. Variable pre-transfusion patient
5 identification practices exist in the perioperative setting. Canadian Journal of Anaesthesia.
6 2009; 56(12):901-907
- 7 61 Busby H. Informed consent to blood transfusion in the NHS: 'doing consent' versus 'what
8 consent can do'. Transfusion Medicine. 2013; 23:43-44
- 9 62 Busby H, Farrell A, Kent J. Risk, safety and consent in blood services in the UK: exploring the
10 perspectives of patients, professionals and policy makers. Transfusion Medicine. 2012; 22:42-
11 43
- 12 63 Cabral KP, Fraser GL, Duprey J, Gibbons BA, Hayes T, Florman JE et al. Prothrombin complex
13 concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
14 Clinical Neurology and Neurosurgery. 2013; 115(6):770-774
- 15 64 Cacheux C, Faraoni D, Van Aelbrouck C, Ickx B, Huybrechts I, Van Obbergh L. Effect of high
16 versus low dose of tranexamic acid (TXA) on fibrinolysis during cardiac surgery. European
17 Journal of Anaesthesiology. 2012; 29:95
- 18 65 Callow CR, Swindell R, Randall W, Chopra R. The frequency of bleeding complications in
19 patients with haematological malignancy following the introduction of a stringent
20 prophylactic platelet transfusion policy. British Journal of Haematology. 2002; 118(2):677-682
- 21 66 Cameron B, Rock G, Olberg B, Neurath D. Evaluation of platelet transfusion triggers in a
22 tertiary-care hospital. Transfusion. 2007; 47(2):206-211
- 23 67 Campbell J, Holland C, Richens D, Skinner H. Impact of cell salvage during cardiac surgery on
24 the thrombelastomeric coagulation profile: a pilot study. Perfusion. 2012; 27(3):221-224
- 25 68 Canan CE, Myers JA, Owens RK, Crawford CH, Djurasovic M, Burke LO et al. Blood salvage
26 produces higher total blood product costs in single-level lumbar spine surgery. Spine. 2013;
27 38(8):703-708
- 28 69 Cankovic KM, Petrovic I. Content analysis of book of impressions as a method of evaluating
29 clinical transfusion therapeutic treatment. Vox Sanguinis. 2009; 96:187
- 30 70 Cankovic KM, Petrovic IB. The effects of doctor-patient relationship in transfusion therapy.
31 Vox Sanguinis. 2011; 101:88-89
- 32 71 Carino G, Tsapenko A, Sweeney J. Fresh frozen plasma use before line insertion in critically-ill
33 patients with coagulation abnormalities. Critical Care Medicine. 2009; 37(12 Suppl):A468
- 34 72 Carruthers J, O'Hoski P, Warkentin TE, Heddle NM. A survey of transfusion practice related to
35 informed consent and post transfusion notification. Canadian Journal of Medical Laboratory
36 Science. 2001; 63(5):179-188
- 37 73 Carson JL, Chen AY. In search of the transfusion trigger. Clinical Orthopaedics and Related
38 Research. 1998;(357):30-35

- 1 74 Carson JL, Terrin ML, Barton FB, Aaron R, Greenburg AG, Heck DA et al. A pilot randomized
2 trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following
3 hip fracture. *Transfusion*. 1998; 38(6):522-529
- 4 75 Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ et al. Liberal versus
5 restrictive transfusion thresholds for patients with symptomatic coronary artery disease.
6 *American Heart Journal*. 2013; 165(6):964-971
- 7 76 Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK et al. Red blood cell
8 transfusion: a clinical practice guideline from the AABB*. *Annals of Internal Medicine*. 2012;
9 157(1):49-58
- 10 77 Carson JL, Hill S, Carless P, Hebert P, Henry D. Transfusion triggers: a systematic review of the
11 literature. *Transfusion Medicine Reviews*. 2002; 16(3):187-199
- 12 78 Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG et al. Liberal or
13 restrictive transfusion in high-risk patients after hip surgery. *New England Journal of*
14 *Medicine*. 2011; 365(26):2453-2462
- 15 79 Casbard AC, Williamson LM, Murphy MF, Rege K, Johnson T. The role of prophylactic fresh
16 frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A
17 systematic review. *Anaesthesia*. 2004; 59(6):550-558
- 18 80 Cassidy SK, Wenzel J, Dilley M, Livingston M, Mascotti K. Transfusion consent: empowering
19 the patient. *Transfusion*. 2013; 53:233A
- 20 81 Cavolli R, Uymaz B, Memishaj S, Eren NT. Cell saver in off-pump surgery. *Heart Surgery Forum*.
21 2011; 14:S35
- 22 82 Celebi N, Celebioglu B, Selcuk M, Canbay O, Karagoz AH, Aypar U. The role of antifibrinolytic
23 agents in gynecologic cancer surgery. *Saudi Medical Journal*. 2006; 27(5):637-641
- 24 83 Chan CC, Chan YY, Tanweer F. Systematic review and meta-analysis of the use of tranexamic
25 acid in tonsillectomy. *European Archives of Oto-Rhino-Laryngology*. 2013; 270(2):735-748
- 26 84 Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood
27 transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-
28 adjusted study sequential analysis. *JAMA Internal Medicine*. 2013; 173(2):132-139
- 29 85 Chen CC, Wang CC, Wang CP, Lin TH, Lin WD, Liu SA. Prospective, randomized, controlled trial
30 of tranexamic acid in patients who undergo head and neck procedures. *Otolaryngology--Head*
31 *and Neck Surgery*. 2008; 138(6):762-767
- 32 86 Chen TT, Jiandong L, Wang G, Jiang SL, Li LB, Gao CQ. Combined treatment of ulinastatin and
33 tranexamic acid provides beneficial effects by inhibiting inflammatory and fibrinolytic
34 response in patients undergoing heart valve replacement surgery. *Heart Surgery Forum*. 2013;
35 16(1):E38-E47
- 36 87 Chen Y, Tai BC, Nayak D, Kumar N, Chua KH, Lim JW et al. Blood loss in spinal tumour surgery
37 and surgery for metastatic spinal disease: a meta-analysis. *Bone and Joint Journal*. 2013; 95-
38 B(5):683-688

- 1 88 Cherian JJ, Kapadia BH, Issa K, Banerjee S, McInerney VK, Harwin SF et al. Preoperative blood
2 management strategies for total hip arthroplasty. *Surgical Technology International*. 2013;
3 23:261-266
- 4 89 Cheriyan T, Bianco K, Maier II SP, Slobodyanyuk K, Schwab FJ, Lonner BS et al. Efficacy of
5 tranexamic acid and aminocaproic acid on bleeding in spine surgery: A meta-analysis. *Spine*
6 *Journal*. 2013; 13(9 Suppl 1):S81
- 7 90 Chirico G, Beccagutti F, Sorlini A, Motta M, Perrone B. Red blood cell transfusion in preterm
8 infants: restrictive versus liberal policy. *Journal of Maternal-Fetal and Neonatal Medicine*.
9 2011; 24 Suppl 1:20-22
- 10 91 Choi JS, Hong CH, Kwack MJ, Lee CK, Cho Y, Park JH. Establishment of computerized clinical
11 decision support program for improving transfusion practice. *Vox Sanguinis*. 2014; 107:21
- 12 92 Cholette J, Powers K, Alfieris G, Angona R, Henrichs K, Blumberg N. Cell saver for volume
13 replacement in children following cardiopulmonary bypass reduces the number of RBC and
14 blood product transfusions and donor exposures. *Critical Care Medicine*. 2011; 39:7
- 15 93 Cholette JM, Powers KS, Alfieris GM, Angona R, Henrichs KF, Masel DS et al. Transfusion of
16 salvaged blood in pediatric heart surgery reduces allogeneic transfusions: a prospective,
17 randomized trial. *Transfusion*. 2012; 52:121A
- 18 94 Cholette JM, Powers KS, Alfieris GM, Angona R, Henrichs KF, Masel D et al. Transfusion of cell
19 saver salvaged blood in neonates and infants undergoing open heart surgery significantly
20 reduces RBC and coagulant product transfusions and donor exposures: results of a
21 prospective, randomized, clinical trial. *Pediatric Critical Care Medicine*. 2013; 14(2):137-147
- 22 95 Chong CT, Lew TWK, Kuperan P, Tan JJE, Tan HL, Kwek TK. Rapid reversal of coagulopathy in
23 warfarin-related intracranial haemorrhages with prothrombin complex concentrates.
24 *Anaesthesia and Intensive Care*. 2010; 38(3):474-480
- 25 96 Christabel A, Muthusekhar MR, Narayanan V, Ashok Y, Soh CL, Ilangovan M et al. Effectiveness
26 of tranexamic acid on intraoperative blood loss in isolated Le Fort I osteotomies - a
27 prospective, triple blinded randomized clinical trial. *Journal of Cranio-Maxillo-Facial Surgery*.
28 2014; 42(7):1221-1224
- 29 97 Chu M, Losenno K, Moore K, Berta D, Hewitt J, Ralley F. Blood conservation strategies reduce
30 the need for transfusions in ascending and aortic arch surgery. *Perfusion*. 2013; 28(4):315-321
- 31 98 Chua D, Amadio A, San C. Epoetin dosing for blood conservation in Jehovah's witness patients
32 undergoing cardiac surgery-a systematic review. *Canadian Journal of Cardiology*. 2014; 30(10
33 Suppl 1):S234
- 34 99 Cid J, Lozano M. Lower or higher doses for prophylactic platelet transfusions: results of a
35 meta-analysis of randomized controlled trials. *Transfusion*. 2007; 47(3):464-470
- 36 100 Clark IR. Hospital blood bank laboratory data processing system. *Journal of Clinical Pathology*.
37 1984; 37(10):1157-1166
- 38 101 Clifford L, Singh A, Wilson GA, Toy P, Gajic O, Malinchoc M et al. Electronic health record
39 surveillance algorithms facilitate the detection of transfusion-related pulmonary
40 complications. *Transfusion*. 2013; 53(6):1205-1216

- 1 102 Collaborators Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: a
2 nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). *BMJ*. 2011;
3 343:d3795
- 4 103 Colomo A, Hernandez G, Muñiz-Diaz E, Madoz P, Aracil C, Alvarez-Urturi C. Transfusion
5 strategies in patients with cirrhosis and acute gastrointestinal bleeding. *Hepatology*. 2008;
6 48(4 Suppl):413A
- 7 104 Cong Z, Ireland A, Stull D, McGarvey N, Brooks A, Kleinman L. Patients experience with
8 treatments of chemotherapy induced anemia (CIA) and myelodysplastic syndromes (MDS).
9 *European Journal of Cancer, Supplement*. 2009; 7(2-3):199-200
- 10 105 Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW et al. Conservative
11 versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot
12 Study). *American Journal of Cardiology*. 2011; 108(8):1108-1111
- 13 106 Corkery C, Charlewood R, Rishworth S, Wright A, King F, Thrift L et al. Recipients' perceptions
14 of red cell transfusions and Anti-D administration. *Transfusion Medicine*. 2013; 23(4):296
- 15 107 Corwin HL. Anemia and blood transfusion in the critically ill patient: role of erythropoietin.
16 *Critical Care*. 2004; 8 Suppl 2:S42-S44
- 17 108 Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S et al. Efficacy and safety of
18 epoetin alfa in critically ill patients. *New England Journal of Medicine*. 2007; 357(10):965-976
- 19 109 Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ et al. Efficacy of recombinant
20 human erythropoietin in critically ill patients: a randomized controlled trial. *JAMA*. 2002;
21 288(22):2827-2835
- 22 110 Cottrell S, Davidson V. National audit of bedside transfusion practice. *Nursing Standard*. 2013;
23 27(43):41-48
- 24 111 Court E, Robinson J, Hocken D, Venn M, Caldwell S. Re-audit of informed consent and patient
25 understanding of blood transfusion. *Transfusion Medicine*. 2012; 22:14-15
- 26 112 Court EL, Robinson JA, Hocken DB. An evaluation of informed consent and patient
27 understanding of blood transfusion. *British Journal of Haematology*. 2010; 149:64
- 28 113 Crotty B. Recycling blood: sharing the benefits of cell salvage. *Applied Health Economics and
29 Health Policy*. 2006; 5(1):5-10
- 30 114 Cuenca J, Garcia-Erce JA, Martinez F, Cardona R, Perez-Serrano L, Munoz M. Preoperative
31 haematinics and transfusion protocol reduce the need for transfusion after total knee
32 replacement. *International Journal of Surgery*. 2007; 5(2):89-94
- 33 115 Curley GF, Shehata N, Mazer CD, Hare GMT, Friedrich JO. Transfusion triggers for guiding RBC
34 transfusion for cardiovascular surgery: a systematic review and meta-analysis. *Critical Care
35 Medicine*. 2014; 42(12):2611-2624
- 36 116 Dadure C, Sauter M, Bringuier S, Bigorre M, Raux O, Rochette A et al. Intraoperative
37 tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a
38 randomized double-blind study. *Anesthesiology*. 2011; 114(4):856-861

- 1 117 Dalmau A, Sabate A, Acosta F, Garcia-Huete L, Koo M, Sansano T et al. Tranexamic acid
2 reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver
3 transplantation. *Anesthesia and Analgesia*. 2000; 91(1):29-34
- 4 118 Damgaard S, Nielsen CH, Andersen LW, Bendtzen K, Tvede M, Steinbruchel DA. Cell saver for
5 on-pump coronary operations reduces systemic inflammatory markers: a randomized trial.
6 *Annals of Thoracic Surgery*. 2010; 89(5):1511-1517
- 7 119 Dara SI, Rana R, Afessa B, Moore SB, Gajic O. Fresh frozen plasma transfusion in critically ill
8 medical patients with coagulopathy. *Critical Care Medicine*. 2005; 33(11):2667-2671
- 9 120 Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell
10 salvage and alternative methods of minimising perioperative allogeneic blood transfusion: A
11 systematic review and economic model. *Health Technology Assessment*. 2006; 10(44):1-114
- 12 121 Davis R, Murphy MF, Sud A, Noel S, Moss R, Asgheddi M et al. Patient involvement in blood
13 transfusion safety: patients' and healthcare professionals' perspective. *Transfusion Medicine*.
14 2012; 22(4):251-256
- 15 122 de Gast-Bakker DH, de Wilde RBP, Hazekamp MG, Sojak V, Zwaginga JJ, Wolterbeek R et al.
16 Safety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery
17 patients: a randomized controlled trial. *Intensive Care Medicine*. 2013; 39(11):2011-2019
- 18 123 Del Campo C, Lukman H, Mehta H, McKenzie FN. Iron therapy after cardiac operation: one
19 prescription less? *Journal of Thoracic and Cardiovascular Surgery*. 1982; 84(4):631-633
- 20 124 Desjardins P, Turgeon AF, Tremblay MH, Lauzier F, Zarychanski R, Boutin A et al. Hemoglobin
21 levels and transfusions in neurocritically ill patients: a systematic review of comparative
22 studies. *Critical Care*. 2012; 16(2):R54
- 23 125 Desmettre T, Dubart AE, Capellier G, Fanara B, Puyraveau M, Kepka S et al. Emergency
24 reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective
25 multicenter two year French study from 2006 to 2008. *Thrombosis Research*. 2012;
26 130(3):e178-e183
- 27 126 Despotis GJ, Grishaber JE, Goodnough LT. The effect of an intraoperative treatment algorithm
28 on physicians' transfusion practice in cardiac surgery. *Transfusion*. 1994; 34(4):290-296
- 29 127 Dhariwal SK, Khan KS, Allard S, Wilson M, Moore P, SALVO study group. Does current evidence
30 support the use of intraoperative cell salvage in reducing the need for blood transfusion in
31 caesarean section? *Current Opinion in Obstetrics and Gynecology*. 2014; 26(6):425-430
- 32 128 Diedrich B, Remberger M, Shanwell A, Svahn BM, Ringden O. A prospective randomized trial
33 of a prophylactic platelet transfusion trigger of 10×10^9 per L versus 30×10^9 per L in
34 allogeneic hematopoietic progenitor cell transplant recipients. *Transfusion*. 2005; 45(7):1064-
35 1072
- 36 129 Dobosz B, Dutka J, Dutka L, Maleta P. Clinical and cost effectiveness-related aspects of
37 retransfusion in total hip and knee arthroplasty. *Ortopedia, Traumatologia, Rehabilitacja*.
38 2012; 14(5):421-428
- 39 130 Doussau A, Perez P, Puntous M, Calderon J, Jeanne M, Germain C et al. Fresh-frozen plasma
40 transfusion did not reduce 30-day mortality in patients undergoing cardiopulmonary bypass

- 1 cardiac surgery with excessive bleeding: the PLASMACARD multicenter cohort study.
2 Transfusion. 2014; 54(4):1114-1124
- 3 131 Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A et al. Poor
4 prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal.
5 Stroke; a Journal of Cerebral Circulation. 2012; 43(7):1812-1817
- 6 132 Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE. Management of anaemia: a critical
7 and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.
8 Pharmacoeconomics. 2008; 26(2):99-120
- 9 133 Duran de la Fuente P, Garcia-Fernandez J, Perez-Lopez C, Carceller F, Gilsanz RF. Usefulness of
10 tranexamic acid in cranial remodeling surgery. Revista Espanola De Anestesiologia y
11 Reanimacion. 2003; 50(8):388-394
- 12 134 Dzik S. Radio frequency identification for prevention of bedside errors. Transfusion. 2007; 47
- 13 135 Dzik WH, Corwin H, Goodnough LT, Higgins M, Kaplan H, Murphy M et al. Patient safety and
14 blood transfusion: new solutions. Transfusion Medicine Reviews. 2003; 17(3):169-180
- 15 136 Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Current
16 Hematology Reports. 2004; 3(5):324-330
- 17 137 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of
18 rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-
19 controlled, crossover study in healthy subjects. Circulation. 2011; 124(14):1573-1579
- 20 138 Elgafy H, Bransford RJ, McGuire RA, Dettori JR, Fischer D. Blood loss in major spine surgery:
21 are there effective measures to decrease massive hemorrhage in major spine fusion surgery?
22 Spine. 2010; 35(9 Suppl):S47-S56
- 23 139 Espahbod C, Veitz-Keenan A. Tranexamic acid reduces intraoperative blood loss in
24 orthognathic surgery. Evidence-Based Dentistry. 2014; 15(2):63
- 25 140 Estcourt L, McSparran W, Dhesi A. The new platelet transfusion mobile site-a bedside tool to
26 aid decision making. Transfusion Medicine. 2013; 23:45
- 27 141 Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A et al. Prophylactic
28 platelet transfusion for prevention of bleeding in patients with haematological disorders after
29 chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews.
30 2012; Issue 5:CD004269
- 31 142 Estcourt LJ, Stanworth S, Doree C, Trivella M, Hopewell S, Murphy MF et al. Different doses of
32 prophylactic platelet transfusion for preventing bleeding in patients with haematological
33 disorders after chemotherapy or stem cell transplantation. Cochrane Database of Systematic
34 Reviews. 2014; Issue 3:CD010984. DOI:10.1002/14651858.CD010984
- 35 143 Faraoni D, Van der Linden P. What do we know about the use of tranexamic acid in pediatric
36 cardiac surgery? Transfusion Alternatives in Transfusion Medicine. 2011; 12(1):39
- 37 144 Faraoni D, Goobie SM. The efficacy of antifibrinolytic drugs in children undergoing noncardiac
38 surgery: a systematic review of the literature. Anesthesia and Analgesia. 2014; 118(3):628-636

- 1 145 Faraoni D, Willems A, Melot C, De Hert S, Van der Linden P. Efficacy of tranexamic acid in
2 paediatric cardiac surgery: a systematic review and meta-analysis. *European Journal of*
3 *Cardio-Thoracic Surgery*. 2012; 42(5):781-786
- 4 146 Febra C, Ressurreicao M, Conceicao A, Melo F, Pimentel I, Soares F et al. Improving patient
5 safety in blood transfusion: An innovative application of informatics system managing blood
6 transfusion process. *Vox Sanguinis*. 2011; 101:83
- 7 147 Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tonnesen E, Ingerslev J et al.
8 Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl
9 starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled
10 clinical trial. *Journal of Thrombosis and Haemostasis*. 2009; 7(5):795-802
- 11 148 Finlay HE, Cassorla L, Feiner J, Toy P. Designing and testing a computer-based screening
12 system for transfusion-related acute lung injury. *American Journal of Clinical Pathology*. 2005;
13 124(4):601-609
- 14 149 Fischer M, Matsuo K, Gonen M, Grant F, Dematteo RP, D'Angelica MI et al. Relationship
15 between intraoperative fluid administration and perioperative outcome after
16 pancreaticoduodenectomy: results of a prospective randomized trial of acute normovolemic
17 hemodilution compared with standard intraoperative management. *Annals of Surgery*. 2010;
18 252(6):952-958
- 19 150 Foss NB, Kristensen MT, Jensen PS, Palm H, Krashennikoff M, Kehlet H. The effects of liberal
20 versus restrictive transfusion thresholds on ambulation after hip fracture surgery.
21 *Transfusion*. 2009; 49(2):227-234
- 22 151 French CJ, Bellomo R, Angus P. Cryoprecipitate for the correction of coagulopathy associated
23 with liver disease. *Anaesthesia and Intensive Care*. 2003; 31(4):357-361
- 24 152 Friedman MT, Aksamawati D, AW, Batra R, Daniel S, Hoehn D, Mondolfi Paniz AE et al. Study
25 to assess transfusion consent. *Transfusion*. 2011; 51:193A-194A
- 26 153 Froessler B, Tufanaru C, Cyna A, Pearson A. Preoperative anemia management with
27 intravenous iron: a systematic review. *JBIC Database of Systematic Reviews and*
28 *Implementation Reports*. 2013; 11(10):157-189
- 29 154 Froessler B, Tufanaru C, Pearson A, Cyna A. Effectiveness and efficiency of pre-operative
30 anaemia management with intravenous iron: A systematic review. *JBIC Library of Systematic*
31 *Reviews*. 2012; 10(14 Suppl)
- 32 155 Fu DJ, Chen C, Guo L, Yang L. Use of intravenous tranexamic acid in total knee arthroplasty: a
33 meta-analysis of randomized controlled trials. *Chinese Journal of Traumatology*. 2013;
34 16(2):67-76
- 35 156 Galas F, Hajjar L, Sorensen B, Almeida J, Sundin M, Guimaraes V et al. Randomized
36 comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in pediatric
37 cardiac surgery (FICCS study). *Critical Care*. 2012; 16:S156-S157
- 38 157 Galusha C, Brown M, Kelly J. Bedside bar codes: protecting patients and nurses. *Online Journal*
39 *of Nursing Informatics*. 2003; 7(3):-6p

- 1 158 Gandhi R, Evans HMK, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of
2 blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Research Notes. 2013;
3 6:184
- 4 159 Garg B, Dhatt S, Chakraborty S. Use of single-dose tranexamic acid to reduce blood loss in
5 operative thoracolumbar trauma: a comparative study. Spine Journal. 2012; 12(9 Suppl 1):93S
- 6 160 Gautam PL, Katyal S, Yamin M, Singh A. Effect of tranexamic acid on blood loss and
7 transfusion requirement in total knee replacement in the Indian population: A case series.
8 Indian Journal of Anaesthesia. 2011; 55(6):590-593
- 9 161 Gautam VK, Sambandam B, Singh S, Gupta P, Gupta R, Maini L. The role of tranexamic acid in
10 reducing blood loss in total knee replacement. Journal of Clinical Orthopaedics and Trauma.
11 2013; 4(1):36-39
- 12 162 Gauvin F, Spinella PC, Lacroix J, Choker G, Ducruet T, Karam O et al. Association between
13 length of storage of transfused red blood cells and multiple organ dysfunction syndrome in
14 pediatric intensive care patients. Transfusion. 2010; 50(9):1902-1913
- 15 163 George DA, Sarraf KM, Nwaboku H. Single perioperative dose of tranexamic acid in primary
16 hip and knee arthroplasty. European Journal of Orthopaedic Surgery and Traumatology. 2015;
17 25:129-133
- 18 164 Gill JB, Chase E, Rosenstein AD. The use of tranexamic acid in revision total hip arthroplasty: a
19 pilot study. Current Orthopaedic Practice. United States 2009; 20(2):152-156
- 20 165 Gill JB, Chin Y, Levin A, Feng D. The use of antifibrinolytic agents in spine surgery. A meta-
21 analysis. Journal of Bone and Joint Surgery American Volume. 2008; 90(11):2399-2407
- 22 166 Gillette BP, Maradit Kremers H, Duncan CM, Smith HM, Trousdale RT, Pagnano MW et al.
23 Economic impact of tranexamic acid in healthy patients undergoing primary total hip and
24 knee arthroplasty. Journal of Arthroplasty. 2013; 28(8 Suppl):137-139
- 25 167 Goddard K, Shabestari O, Kay JDS, Roudsari A. Formatively evaluating the importance of
26 different aspects of an electronic blood transfusion system from the end users' point of view:
27 A questionnaire study. Studies in Health Technology and Informatics. 2010; 160(Part 1):1211-
28 1215
- 29 168 Golab HD, Scohy TV, de Jong PL, Takkenberg JJM, Bogers AJJC. Intraoperative cell salvage in
30 infants undergoing elective cardiac surgery: a prospective trial. European Journal of Cardio-
31 Thoracic Surgery. 2008; 34(2):354-359
- 32 169 Goldenberg NA, Manco-Johnson MJ. Pediatric hemostasis and use of plasma components.
33 Best Practice and Research Clinical Haematology. 2006; 19(1):143-155
- 34 170 Gomez C, Arzani Y, Ochoa J, Bertolotti A, Absi D. Prophylactic use of tranexamic acid and e-
35 aminocaproic acid in heart surgery. British Journal of Anaesthesia. 2012; 108:ii362-ii363
- 36 171 Goobie SM, Meier PM, Pereira LM, McGowan FX, Prescilla RP, Scharp LA et al. Efficacy of
37 tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
38 Anesthesiology. 2011; 114(4):862-871
- 39 172 Goodnough LT, McCullough J, Slichter S, Strauss R, Lin J-S, Conlan M. A platelet transfusion
40 threshold of 20 x 10⁹/L compared to 10 x 10⁹/L is associated with increased pre-transfusion

- 1 bleeding and increased platelet transfusions: results of the SPRINT study. *Transfusion*. 2002;
2 42(9S):17S
- 3 173 Goodnough LT, Price TH, Parvin CA, Friedman KD, Vogler WR, Khan N et al. Erythropoietin
4 response to anaemia is not altered by surgery or recombinant human erythropoietin therapy.
5 *British Journal of Haematology*. 1994; 87(4):695-699
- 6 174 Goodnough LT, Shah N, Hadhazy E, Shieh L, Maggio P. Improved hospital-wide RBC utilization
7 via clinical decision support is associated with stable or improving patient outcomes. *Blood*.
8 2013; 122(21)
- 9 175 Goodnough L. Operational, quality, and risk management in the transfusion service: lessons
10 learned. *Transfusion Medicine Reviews*. 2012; 26(3):252-261
- 11 176 Goodnough LT, Viele M, Fontaine MJ, Jurado C, Stone N, Quach P et al. Implementation of a
12 two-specimen requirement for verification of ABO/Rh for blood transfusion. *Transfusion*.
13 2009; 49(7):1321-1328
- 14 177 Gourlay T, Gunaydin S. Clinical outcome of transfusion processed by ultrafiltration in patients
15 undergoing coronary bypass. *Transfusion Medicine*. 2013; 23:28
- 16 178 Goz V, Slobodyanyuk K, Cheriyan T, Schwab FJ, Verma K, Hoelscher CM et al. Antifibrinolytics
17 reduce blood loss in adult spinal deformity surgery: A prospective randomized controlled trial.
18 *Spine Journal*. 2013; 13(9 Suppl 1):1S
- 19 179 Grassin-Delyle S, Couturier R, Abe E, Alvarez JC, Devillier P, Urien S. A practical tranexamic
20 acid dosing scheme based on population pharmacokinetics in children undergoing cardiac
21 surgery. *Anesthesiology*. 2013; 118(4):853-862
- 22 180 Green M. Development. Introducing an electronic blood-tracking system. *Nursing Times*.
23 2008; 104(6):33-34
- 24 181 Gregurek S, Waters K, Cruz JL, Smith DS. Adult transfusion order sets are a useful adjunct in
25 blood utilization programs. *Transfusion*. 2009; 49:174A
- 26 182 Gregurek SF, Waters KM, Limiac A, Smith DS. Development and validation of a robust
27 automated screening tool to categorize transfusion indication during blood utilization review.
28 *Transfusion*. 2010; 50:267A
- 29 183 Grimm E, Friedberg RC, Wilkinson DS, Aubuchon JP, Souers RJ, Lehman CM. Blood bank safety
30 practices: mislabeled samples and wrong blood in tube--a Q-Probes analysis of 122 clinical
31 laboratories. *Archives of Pathology and Laboratory Medicine*. 2010; 134(8):1108-1115
- 32 184 Grover M, Talwalkar S, Casbard A, Boralessa H, Contreras M, Boralessa H et al. Silent
33 myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of
34 transfusion strategy in lower limb arthroplasty. *Vox Sanguinis*. 2006; 90(2):105-112
- 35 185 Grundsell H, Larsson G, Bekassy Z. Use of an antifibrinolytic agent (tranexamic acid) and
36 lateral sutures with laser conization of the cervix. *Obstetrics and Gynecology*. 1984; 64(4):573-
37 576
- 38 186 Guay J, de Moerloose P, Lasne D. Minimizing perioperative blood loss and transfusions in
39 children. *Canadian Journal of Anaesthesia*. 2006; 53(6 Suppl):S59-S67

- 1 187 Guerra Hernando JM, Bargay LJ, Cladera SA, Alcover AS, Ponseti Socias M, Del Campo GR et al.
2 Experience in integration of the blood transfusion process into computerized clinical record,
3 from request to results. Improvements in ergonomics and security. *Transfusion*. 2010;
4 50:187A-188A
- 5 188 Gumpeni P, Wolf CFW. New technologies for monitoring and improving the safe
6 administration of blood products. *Laboratory Medicine*. 2006; 37(12):737-741
- 7 189 Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to
8 decrease blood loss and transfusion requirements for liver transplantation. *Cochrane*
9 *Database of Systematic Reviews*. 2011; Issue 12:CD009052
- 10 190 Haien Z, Yong J, Baoan M, Mingjun G, Qingyu F. Post-operative auto-transfusion in total hip or
11 knee arthroplasty: a meta-analysis of randomized controlled trials. *PloS One*. 2013;
12 8(1):e55073
- 13 191 Halder S, Samanta B, Sardar R, Chattopadhyay S. Tranexomic acid used before caesarean
14 section reduces blood loss based on pre- and postoperative hemoglobin level: a case-control
15 study. *Journal of the Indian Medical Association*. 2013; 111(3):184-186
- 16 192 Hardy JF. Should we reconsider triggers for red blood cell transfusion? *Acta Anaesthesiologica*
17 *Belgica*. 2003; 54(4):287-295
- 18 193 Hashimoto T, Kokudo N, Orii R, Seyama Y, Sano K, Imamura H et al. Intraoperative blood
19 salvage during liver resection: a randomized controlled trial. *Annals of Surgery*. 2007;
20 245(5):686-691
- 21 194 Hassani E, Mahoori A, Mehdizadeh H, Noroozinia H, Aghdashi MM, Saeidi M. The effects of
22 tranexamic acid on postoperative bleeding in coronary artery bypass graft surgery. *Tehran*
23 *University Medical Journal*. 2012; 70(3):176-182
- 24 195 Hearnshaw SA, Logan RFA, Palmer KR, Card TR, Travis SPL, Murphy MF. Outcomes following
25 early red blood cell transfusion in acute upper gastrointestinal bleeding. *Alimentary*
26 *Pharmacology and Therapeutics*. 2010; 32(2):215-224
- 27 196 Hebert PC. Red cell transfusion strategies in the ICU. *Transfusion Requirements in Critical Care*
28 *Investigators and the Canadian Critical Care Trials Group*. *Vox Sanguinis*. 2000; 78 Suppl 2:167-
29 177
- 30 197 Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of
31 prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia:
32 10,000/microL versus 20,000/microL. *Journal of Clinical Oncology*. 1997; 15(3):1143-1149
- 33 198 Heddle NM, Cook RJ, Timmouth A, Kouroukis CT, Hervig T, Klapper E et al. A randomized
34 controlled trial comparing standard- and low-dose strategies for transfusion of platelets
35 (SToP) to patients with thrombocytopenia. *Blood*. 2009; 113(7):1564-1573
- 36 199 Herman JH, Klumpp TR, Christman RA, Russo RR, Goldberg SL, Mangan KF. The effect of
37 platelet dose on the outcome of prophylactic platelet transfusion. *Transfusion*. 1995;
38 35(10S):46S
- 39 200 Hesselvik F, Brodin B, Carlsson C, Cedergren B, Jorfeldt L, Lieden G. Cryoprecipitate infusion
40 fails to improve organ function in septic shock. *Critical Care Medicine*. 1987; 15(5):475-483

- 1 201 Hoelscher C, Verma K, Errico T, Dryer J, Huncke T, Boenigk K et al. Are anti-fibrinolytics
2 effective at reducing peri-operative blood loss in adolescent idiopathic scoliosis? *Spine*
3 *Journal*. 2011; 11(10 Suppl 1):67S
- 4 202 Hogan M, Needham A, Ortmann E, Bottrill F, Besser M, Klein A. A randomized controlled trial
5 of the effect of concentrating residual cardiopulmonary bypass blood using Hemosep on
6 patient haematocrit after cardiac surgery. *Applied Cardiopulmonary Pathophysiology*. 2014;
7 18:51-52
- 8 203 Hogshire L, Carson JL. Red blood cell transfusion: what is the evidence when to transfuse?
9 *Current Opinion in Hematology*. 2013; 20(6):546-551
- 10 204 Holcomb JB, Fox EE, Zhang X, White N, Wade CE, Cotton BA et al. Cryoprecipitate use in the
11 PROMMTT study. *Journal of Trauma and Acute Care Surgery*. 2013; 75(1 Suppl 1):S31-S39
- 12 205 Holst LB, Haase N, Wetterslev J, Wernerman J, Aneman A, Guttormsen AB et al. Transfusion
13 requirements in septic shock (TRISS) trial - comparing the effects and safety of liberal versus
14 restrictive red blood cell transfusion in septic shock patients in the ICU: protocol for a
15 randomised controlled trial. *Trials*. 2013; 14:150
- 16 206 Huang F, Wu D, Ma G, Yin Z, Wang Q. The use of tranexamic acid to reduce blood loss and
17 transfusion in major orthopedic surgery: a meta-analysis. *Journal of Surgical Research*. 2014;
18 186(1):318-327
- 19 207 Huet C, Salmi LR, Fergusson D, Koopman-Van Gemert AW, Rubens F, Laupacis A. A meta-
20 analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood
21 transfusion in cardiac and orthopedic surgery. *International Study of Perioperative*
22 *Transfusion (ISPOT) Investigators. Anesthesia and Analgesia*. 1999; 89(4):861-869
- 23 208 Hutton B, Joseph L, Fergusson D, Mazer D, Shapiro S, Tinmouth A. Combining randomized and
24 observational data using network meta-analysis to explore drug safety: The case of
25 antifibrinolytics in cardiac surgery. *Clinical Trials*. 2012; 9(4):483-484
- 26 209 Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A. Risks of harms using
27 antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of
28 randomised and observational studies. *BMJ*. 2012; 345:e5798
- 29 210 Huynh TK, Costello JL, Rebeck JA. Optimizing the dose of three-factor prothrombin complex
30 concentrate in traumatic brain injury patients on warfarin therapy. *Pharmacotherapy*. 2014;
31 34(3):260-264
- 32 211 Hwang T-L, Chen M-F. Treatment of severely septic patients with fibrinectin-rich
33 cryoprecipitate: a randomised trial. *Acta Chirurgica - European Journal of Surgery*. 1991;
34 157(11-12):653-655
- 35 212 Ibojie J, Urbaniak SJ. Comparing near misses with actual mistransfusion events: a more
36 accurate reflection of transfusion errors. *British Journal of Haematology*. 2000; 108(2):458-
37 460
- 38 213 Ipema HJ, Tanzi MG. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding
39 after major surgical procedures. *Annals of Pharmacotherapy*. 2012; 46(1):97-107

- 1 214 Irisson E, Hemon Y, Pauly V, Parratte S, Argenson JN, Kerbaul F. Tranexamic acid reduces
2 blood loss and financial cost in primary total hip and knee replacement surgery. *Orthopaedics
3 and Traumatology: Surgery and Research*. France 2012; 98(5):477-483
- 4 215 Islam S, Robertson B, Fulkes V, Robinson S, Harrison C. A pilot survey of patient's perception
5 of a special transfusion card - An inner city teaching Hospital experience. *Transfusion
6 Medicine*. 2011; 21:41
- 7 216 Iyengar A, Scipione CN, Sheth P, Ohye RG, Riegger L, Bove EL et al. Association of
8 complications with blood transfusions in pediatric cardiac surgery patients. *Annals of Thoracic
9 Surgery*. 2013; 96(3):910-916
- 10 217 Jahanshahi J, Hashemian F, Pazira S, Bakhshaei MH, Farahani F, Abasi R et al. Effect of topical
11 tranexamic acid on bleeding and quality of surgical field during functional endoscopic sinus
12 surgery in patients with chronic rhinosinusitis: a triple blind randomized clinical trial. *PLoS
13 One*. 2014; 9(8):e104477
- 14 218 Jairath V, Shakur H, Edwards P, Ker K, Manno D, Gilmore I et al. Update on the halt-it trial
15 progress: tranexamic acid for the treatment of gastrointestinal haemorrhage - an
16 international, randomised, double blind placebo controlled trial. *Gut*. 2014; 63:A120
- 17 219 Jairath V, Kahan BC, Gray A, Dore CJ, Mora A, Dyer C et al. Restrictive vs liberal blood
18 transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster
19 randomized feasibility trial. *Transfusion Medicine Reviews*. 2013; 27(3):146-153
- 20 220 Jaspers A, Baron F, Willems E, Seidel L, Hafraoui K, Vanstraelen G et al. Erythropoietin therapy
21 after allogeneic hematopoietic cell transplantation: A prospective, randomized trial. *Blood*.
22 2014; 124(1):33-41
- 23 221 Jeong O, Park YK. Effect of intravenous iron supplementation for acute postoperative anemia
24 in patients undergoing gastrectomy for gastric carcinoma: a pilot study. *Annals of Surgical
25 Oncology*. 2014; 21(2):547-552
- 26 222 Jimenez-Yuste V, Prim MP, Diego JI, Villar A, Quintana M, Rabanal I et al. Otolaryngologic
27 surgery in children with von Willebrand disease. *Archives of Otolaryngology: Head and Neck
28 Surgery*. 2002; 128(12):1365-1368
- 29 223 Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate
30 for perioperative reversal of vitamin K antagonist treatment in bleeding and non-bleeding
31 patients requiring acute surgical intervention. *Cochrane Database of Systematic Reviews*.
32 2013; Issue 6:CD010555. DOI:10.1002/14651858.CD010555
- 33 224 Johnson RG, Thurer RL, Kruskall MS, Sirois C, Gervino EV, Critchlow J et al. Comparison of two
34 transfusion strategies after elective operations for myocardial revascularization. *Journal of
35 Thoracic and Cardiovascular Surgery*. 1992; 104(2):307-314
- 36 225 Josephson C, Sloan S, Granger S, Castillejo M, Strauss RG, Slichter S et al. Increased incidence
37 of grade 2 and higher bleeding in pediatric PLADO trial patients. *Transfusion*. 2009; 49:19A-
38 20A
- 39 226 Junagade P, Grace R, Gover P. Fixed dose prothrombin complex concentrate for the reversal
40 of oral anticoagulation therapy. *Hematology*. 2007; 12(5):439-440

- 1 227 Kahan BC, Jairath V, Murphy MF, Dore CJ. Update on the transfusion in gastrointestinal
2 bleeding (TRIGGER) trial: statistical analysis plan for a cluster-randomised feasibility trial.
3 *Trials*. 2013; 14:206
- 4 228 Karam O, Tucci M, Ducruet T, Hume HA, Lacroix J, Gauvin F et al. Red blood cell transfusion
5 thresholds in pediatric patients with sepsis. *Pediatric Critical Care Medicine*. 2011; 12(5):512-
6 518
- 7 229 Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Flinck A, Skrtic S et al. Prophylactic fibrinogen
8 infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised
9 pilot study. *Thrombosis and Haemostasis*. 2009; 102(1):137-144
- 10 230 Kashefi P, Heidari SM, Saryazdi H, Javdan M. Evaluation of tranexemic acid effect on blood
11 loss and transfusion in femoral shaft surgery. *Journal of Isfahan Medical School*. 2012; 30(192)
- 12 231 Kaste M, Ramsay M. Tranexamic acid in subarachnoid hemorrhage. A double-blind study.
13 *Stroke; a Journal of Cerebral Circulation*. 1979; 10(5):519-522
- 14 232 Kaufman RM, Assmann SF, Triulzi DJ, Strauss RG, Ness P, Granger S et al. Transfusion-related
15 adverse events in the Platelet Dose study. *Transfusion*. 2015; 55(1):144-153
- 16 233 Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. *Drugs*. 2015; 75:101-
17 127
- 18 234 Kelley TC, Tucker KK, Adams MJ, Dalury DF. Use of tranexamic acid results in decreased blood
19 loss and decreased transfusions in patients undergoing staged bilateral total knee
20 arthroplasty. *Transfusion*. 2014; 54(1):26-30
- 21 235 Kennedy MS, Kalish LA, Mohandas K, Gernsheimer T, Townsend-McCall D, Viral Activation
22 Transfusion Study Group. The transfusion trigger and number of units transfused in patients
23 with HIV: associations with disease stage and functional status. *Transfusion*. 2002; 42(4):456-
24 461
- 25 236 Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and
26 platelet transfusion in trauma. *Journal of Trauma - Injury, Infection and Critical Care*. 2006;
27 60(6 Suppl):S51-S56
- 28 237 Khan Assir MZ, Kamran U, Ahmad HI, Bashir S, Mansoor H, Anees SB et al. Effectiveness of
29 platelet transfusion in dengue fever: a randomized controlled trial. *Transfusion Medicine and
30 Hemotherapy*. 2013; 40(5):362-368
- 31 238 Khan H, Belsher J, Yilmaz M, Afessa B, Winters JL, Moore SB et al. Fresh-frozen plasma and
32 platelet transfusions are associated with development of acute lung injury in critically ill
33 medical patients. *Chest*. 2007; 131(5):1308-1314
- 34 239 Khan MH, Watson HG, Dombrowski SU. Perceived hazards of transfusion: can a clinician tool
35 help patients' understanding? *Transfusion Medicine*. 2012; 22(4):294-297
- 36 240 Kim TK, Chang CB, Koh IJ. Practical issues for the use of tranexamic acid in total knee
37 arthroplasty: a systematic review. *Knee Surgery, Sports Traumatology, Arthroscopy*. 2014;
38 22(8):1849-1858
- 39 241 Klinck JR, Boylan JF, Sandler AN, Greig PD, Roger S, Nierenberg H. Tranexamic acid prophylaxis
40 during liver transplantation: a randomized controlled trial. *Hepatology*. 1993; 18:728

- 1 242 Klumpp TR, Herman JH, Christman RA, Russo RR, Goldberg SL, Macdonald JS et al. The effect
2 of platelet dose on the interval between platelet transfusions in patients undergoing bone
3 marrow or peripheral blood stem cell transplantation. *Proceedings of the American Society of*
4 *Clinical Oncology*. 1995; 14:536
- 5 243 Klumpp TR, Herman JH, Gaughan JP, Russo RR, Christman RA, Goldberg SL et al. Clinical
6 consequences of alterations in platelet transfusion dose: a prospective, randomized, double-
7 blind trial. *Transfusion*. 1999; 39(7):674-681
- 8 244 Knight C, Dano AM, Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC
9 treatment for hemophilia patients with inhibitors. *Advances in Therapy*. 2009; 26(1):68-88
- 10 245 Konig G, Yazer MH, Waters JH. The effect of salvaged blood on coagulation function as
11 measured by thromboelastography. *Transfusion*. 2013; 53(6):1235-1239
- 12 246 Kostousov V, Nguyen K, Hui SR, Teruya J. Influence of apheresis platelets and cryoprecipitate
13 on heparin activity measured by PTT and anti-Xa in vitro. *Transfusion*. 2012; 52:191A
- 14 247 Krafft A, Breymann C. Iron sucrose with and without recombinant erythropoietin for the
15 treatment of severe postpartum anemia: a prospective, randomized, open-label study.
16 *Journal of Obstetrics and Gynaecology Research*. 2011; 37(2):119-124
- 17 248 Kristensen PW, Sorensen LS, Thyregod HC. Autotransfusion of drainage blood in arthroplasty.
18 A prospective, controlled study of 31 operations. *Acta Orthopaedica Scandinavica*. 1992;
19 63(4):377-380
- 20 249 Kumar N, Chen Y, Zaw AS, Nayak D, Ahmed Q, Soong R et al. Use of intraoperative cell-salvage
21 for autologous blood transfusions in metastatic spine tumour surgery: a systematic review.
22 *Lancet Oncology*. 2014; 15(1):e33-e41
- 23 250 Kuo SF, Lin JS, Young LH, Wu CW. Improvement of blood component transfusion
24 appropriateness with a prospective audit program at a medical center: A 2-year experience.
25 *Vox Sanguinis*. 2011; 101:45
- 26 251 Labarinas S, Arni D, Karam O. Plasma in the PICU: why and when should we transfuse? *Annals*
27 *of Intensive Care*. 2013; 3(1):1-7
- 28 252 Lang P, Bierling P, Buisson C, Fruchaud G, Busson M, Belghiti D et al. Influence of
29 posttransplantation blood transfusion on kidney allograft survival: A one-center, double-blind,
30 prospective, randomized study comparing cryopreserved and fresh red blood cell
31 concentrates. *Transplantation Proceedings*. 1993; 25(1):616-618
- 32 253 Latreille M, Fortin S, Lacroix J, Tucci M, Robitaille N. Patient's and their parent's
33 representations of blood and blood transfusion in a children's hospital: an anthropological
34 study. *Transfusion Alternatives in Transfusion Medicine*. 2010; 11:16-17
- 35 254 Lauzier F, Cook D, Griffith L, Upton J, Crowther M. Fresh frozen plasma transfusion in critically
36 ill patients. *Critical Care Medicine*. 2007; 35(7):1655-1659
- 37 255 Leal-Noval SR, Lopez-Irizaro R, Bautista-Paloma J, Casado M, Arellano-Orden V, Leal-Romero M
38 et al. Efficacy of the prothrombin complex concentrate prothromplex in patients requiring
39 urgent reversal of vitamin K antagonists or presenting with uncontrolled bleeding: A
40 retrospective, single center study. *Blood Coagulation and Fibrinolysis*. 2013; 24(8):862-868

- 1 256 Lee BW, Park MG, Cho DY, Park SS, Yeo JK. Preoperative erythropoietin administration in
2 patients with prostate cancer undergoing radical prostatectomy without transfusion. *Korean*
3 *Journal of Urology*. 2014; 55(2):102-105
- 4 257 Lee DH, Mehta MD, James PD. Differences in the perception of blood transfusion risk
5 between laypeople and physicians. *Transfusion*. 2003; 43(6):772-778
- 6 258 Lee SH, Lee SM, Kim CS, Cho HS, Lee J-H, Lee CH et al. Fibrinogen recovery and changes in
7 fibrin-based clot firmness after cryoprecipitate administration in patients undergoing aortic
8 surgery involving deep hypothermic circulatory arrest. *Transfusion*. 2014; 54(5):1379-1387
- 9 259 Leelahanon S, Singhatanadgige S, Luengtaviboon K. Can tranexamic acid improve post
10 cardiopulmonary bypass hemostasis? a double-blind prospective randomized placebo-
11 controlled study. *Thai Journal of Surgery*. 2002; 23:138
- 12 260 Lerner RG, Nelson J, Sorcia E, Grima K, Kancherla RR, Zarou-Naimo CM et al. Evaluation of
13 solvent/detergent-treated plasma in patients with a prolonged prothrombin time. *Vox*
14 *Sanguinis*. 2000; 79(3):161-167
- 15 261 Levy JH, Petrozzino J, Jones C, Hoesche J. Perceptions about 'rapid' warfarin reversal to reduce
16 the international normalized ratio with fresh frozen plasma: a double-blinded survey of U.S.
17 trauma centers. *Journal of Thrombosis and Haemostasis*. 2011; 9:361
- 18 262 Li N, Li P, Liu M, Wang D, Xia L. Comparison between autologous blood transfusion drainage
19 and no drainage/closed-suction drainage in primary total hip arthroplasty: a meta-analysis.
20 *Archives of Orthopaedic and Trauma Surgery*. 2014; 134(11):1623-1631
- 21 263 Li ZJ, Fu X, Xing D, Zhang HF, Zang JC, Ma XL. Is tranexamic acid effective and safe in spinal
22 surgery? A meta-analysis of randomized controlled trials. *European Spine Journal*. 2013;
23 22(9):1950-1957
- 24 264 Lian C-W, Li H, Li Q, Liu B. Tranexamic acid for coronary artery bypass grafting with on-pump:
25 a systematic review. *Chinese Journal of Evidence-Based Medicine*. 2011; 11(2):150-160
- 26 265 Lightdale JR, Randolph AG, Tran CM, Jiang H, Colon A, Houlahan K et al. Impact of a
27 conservative red blood cell transfusion strategy in children undergoing hematopoietic stem
28 cell transplantation. *Biology of Blood and Marrow Transplantation*. 2012; 18(5):813-817
- 29 266 Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in
30 perioperative blood management: a systematic review. *Transfusion Medicine Reviews*. 2013;
31 27(4):221-234
- 32 267 Lin DM, Murphy LS, Tran MH. Use of prothrombin complex concentrates and fibrinogen
33 concentrates in the perioperative setting: a systematic review. *Transfusion Medicine Reviews*.
34 2013; 27(2):91-104
- 35 268 Lin PC, Hsu CH, Chen WS, Wang JW. Does tranexamic acid save blood in minimally invasive
36 total knee arthroplasty? *Clinical Orthopaedics and Related Research*. 2011; 469(7):1995-2002
- 37 269 Liu JM, Peng HM, Shen JX, Qiu GX. A meta-analysis of the effectiveness and safety of using
38 tranexamic acid in spine surgery. *Chinese Journal of Surgery*. 2010; 48(12):937-942

- 1 270 Lowe KC, Farrell K, Ferguson EM, James V. Current perceived risks of transfusion in the UK and
2 relevance to the future acceptance of blood substitutes. *Artificial Cells, Blood Substitutes, and*
3 *Immobilization Biotechnology*. 2001; 29(3):179-189
- 4 271 Lozano M, Basora M, Peidro L, Merino I, Segur JM, Pereira A et al. Effectiveness and safety of
5 tranexamic acid administration during total knee arthroplasty. *Vox Sanguinis*. 2008; 95:39-44
- 6 272 Lu FQ, Wang WM, Yu M. Effect of reducing prophylactic platelet transfusion dose on bleeding
7 in thrombocytopenia patients. *Vox Sanguinis*. 2011; 101:310
- 8 273 Lu FQ, Zhao DW, Peng Y. Clinical study on the effect of reducing prophylactic platelet
9 transfusion dose on bleeding in stable thrombocytopenia patients. *Vox Sanguinis*. 2013;
10 105:262
- 11 274 Lum G. Should the transfusion trigger and hemoglobin low critical limit be identical? *Annals of*
12 *Clinical and Laboratory Science*. 1997; 27(2):130-134
- 13 275 Lundin E, Johansson T, Zachrisson H, Leandersson U, Backman F, Falknas L et al. Single dose of
14 tranexamic acid reduces blood loss and transfusions in surgery for advanced ovarian cancer.
15 *International Journal of Gynecological Cancer*. 2013; 23(8 Suppl 1):63
- 16 276 Lusher JM. Controlled clinical trials with prothrombin complex concentrates. *Progress in*
17 *Clinical and Biological Research*. 1984; 150:277-290
- 18 277 Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC et al. Autoplex versus
19 proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in
20 hemophiliacs with inhibitors to factor VIII. *Blood*. 1983; 62(5):1135-1138
- 21 278 Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-
22 complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic
23 trial. *New England Journal of Medicine*. 1980; 303(8):421-425
- 24 279 Ma A, Smith A, Alston P, Brindle W, Burton G, Manelius I et al. Mechanical cell salvage and off-
25 pump coronary artery bypass grafting surgery: a systematic review and meta-analysis. *Journal*
26 *of Cardiothoracic and Vascular Anesthesia*. 2010; 24(3 Suppl 1):S12-S13
- 27 280 MacGillivray RG, Tarabichi SB, Hawari MF, Raoof NT. Tranexamic acid to reduce blood loss
28 after bilateral total knee arthroplasty: a prospective, randomized double blind study. *Journal*
29 *of Arthroplasty*. 2011; 26(1):24-28
- 30 281 MacLaren R, Gasper J, Jung R, Vandivier RW. Use of exogenous erythropoietin in critically ill
31 patients. *Journal of Clinical Pharmacy and Therapeutics*. 2004; 29(3):195-208
- 32 282 Mahapatra P, Neffendorf JE, Wilson S. Consent for blood transfusions-are we making
33 progress? *Vox Sanguinis*. 2013; 105:62-63
- 34 283 Mai J, Sikand H. Is low dose 3-factor PCC effective for warfarin reversal? *Critical Care*
35 *Medicine*. 2013; 41(12 Suppl 1):A226
- 36 284 Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic
37 acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. *Clinical*
38 *Orthopaedics and Related Research*. 2012; 470(9):2605-2612

- 1 285 Markar SR, Jones GG, Karthikesalingam A, Segaren N, Patel RV. Transfusion drains versus
2 suction drains in total knee replacement: meta-analysis. *Knee Surgery, Sports Traumatology,*
3 *Arthroscopy.* 2012; 20(9):1766-1772
- 4 286 Martinez A, Fernandez De Gamarra A, Font A, Belaouchi M, Gomez AM, Moral V. Predicting
5 blood transfusion needs in off-pump coronary cardiac surgery: development, validation and
6 comparison of a prognostic index. *European Journal of Anaesthesiology.* 2011; 28:82
- 7 287 Martinez-Sanz R, Jimenez JJ, Iribarren JL, De La Llana RJ, Nassar IM, Garrido P et al. Single or
8 double tranexamic acid dose to minimize fibrinolysis and inflammatory response after open
9 heart surgery? a randomized doubleblind phase iv clinical trial. *Heart Surgery Forum.* 2011;
10 14:S117
- 11 288 Mascotti K, Wenzel JJ, Hustead VA, Gulke R, Zier J, Flynn M et al. Standardizing transfusion
12 practices through computerized physician order entry in a pediatric hospital setting.
13 *Transfusion.* 2009; 49:202A
- 14 289 Mason L, Fitzgerald C, Powell-Tuck J, Rice R. Intraoperative cell salvage versus postoperative
15 autologous blood transfusion in hip arthroplasty: a retrospective service evaluation. *Annals of*
16 *the Royal College of Surgeons of England.* 2011; 93(5):398-400
- 17 290 Matkovic M, Vuksanovic M, Putnik S. The efficacy of intraoperative cell salvage during
18 coronary artery bypass grafting. *European Journal of Medical Research.* 2010; 15:223
- 19 291 Matsumoto M, Kawa K, Uemura M, Kato S, Ishizashi H, Isonishi A et al. Prophylactic fresh
20 frozen plasma may prevent development of hepatic VOD after stem cell transplantation via
21 ADAMTS13-mediated restoration of von Willebrand factor plasma levels. *Bone Marrow*
22 *Transplantation.* 2007; 40(3):251-259
- 23 292 McCarthy T, Mullett H, Carey M, Burke TE. Irish orthopaedic patients' attitudes to blood
24 transfusion. *Irish Medical Journal.* 2001; 94(4):110-111
- 25 293 McCrory MC, Strouse JJ, Takemoto C, Easley RB. Safety and efficacy of a manual isovolumetric
26 double volume exchange transfusion protocol in children. *American Journal of Respiratory*
27 *and Critical Care Medicine.* 2010; 181(1 MeetingAbstracts)
- 28 294 Mercuriali F, Gualtieri G, Inghilleri G, Biffi E, Vinci A, Colotti MT. Erythropoietin for autologous
29 blood donation in anemic rheumatoid patients undergoing major orthopedic surgery. *British*
30 *Journal of Haematology.* 1994; 87(Suppl 1):159
- 31 295 Mercuriali F, Inghilleri G, Colotti MT, Fare M, Biffi E, Vinci A et al. Bedside transfusion errors:
32 analysis of 2 years' use of a system to monitor and prevent transfusion errors. *Vox Sanguinis.*
33 1996; 70(1):16-20
- 34 296 Meybohm P, Herrmann E, Nierhoff J, Zacharowski K. Aprotinin may increase mortality in low
35 and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic
36 acid and -aminocaproic acid -- a meta-analysis of randomised and observational trials of over
37 30.000 patients. *PloS One.* 2013; 8(3):e58009
- 38 297 Miao Y-L, Ma H-S, Guo W-Z, Wu J-G, Liu Y, Shi W-Z et al. The efficacy and cost-effectiveness of
39 cell saver use in instrumented posterior correction and fusion surgery for scoliosis in school-
40 aged children and adolescents. *PloS One.* 2014; 9(4)

- 1 298 Mognilevitch M, Sarwahi V. Methods to reduce blood loss in pediatric scoliosis surgery.
2 European Journal of Anaesthesiology. 2011; 28:88-89
- 3 299 Molloy DO, Archbold HA, Ogonda L, McConway J, Wilson RK, Beverland DE. Comparison of
4 topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a
5 prospective, randomised controlled trial. Journal of Bone and Joint Surgery British Volume.
6 2007; 89(3):306-309
- 7 300 Monk TG, Goodnough LT, Brecher ME, Colberg JW, Andriole GL, Catalona WJ. A prospective
8 randomized comparison of three blood conservation strategies for radical prostatectomy.
9 Anesthesiology. 1999; 91(1):24-33
- 10 301 Moonen AFCM, Thomassen BJW, Knoors NT, van Os JJ, Verburg AD, Pilot P. Pre-operative
11 injections of epoetin-alpha versus post-operative retransfusion of autologous shed blood in
12 total hip and knee replacement: a prospective randomised clinical trial. Journal of Bone and
13 Joint Surgery British Volume. 2008; 90(8):1079-1083
- 14 302 Moore K, Berta D, Hewitt J, Ralley F, Chu M. Blood conservation strategies in ascending aortic
15 arch surgery. Canadian Journal of Cardiology. 2011; 27(5 Suppl 1):S194-S195
- 16 303 Morales M, Udina E, Asbert R. Implementation of a program to reduce allogeneic blood
17 transfusion in total hip arthroplasty. European Journal of Anaesthesiology. 2013; 30:96-97
- 18 304 Moret F, Flo A, Escudero A, Masso E. Tranexamic acid reduces postoperative bleeding but not
19 allogeneic transfusion requirements in valve replacement cardiac surgery. European Journal
20 of Anaesthesiology. 2006; 23:2-3
- 21 305 Morgan A, Anderson W, Bevilacqua R, Cohn L, Moore FD, Collins JJJ. Effects of computer-
22 controlled transfusion on recovery from cardiac surgery. Annals of Surgery. 1973; 178(4):391-
23 398
- 24 306 Morgenschweis K, Gierth T, Hering R. Effects of cell saver autologous blood transfusion on
25 allogeneic blood transfusion in patients undergoing primary hip and knee replacement.
26 Transfusion Alternatives in Transfusion Medicine. 2011; 12(1):26
- 27 307 Morris AH. Decision-support for clinicians - How to implement. Journal of Clinical Monitoring
28 and Computing. 2011; 25(1):28-29
- 29 308 Motta M, Del Vecchio A, Perrone B, Ghirardello S, Radicioni M. Fresh frozen plasma use in the
30 NICU: a prospective, observational, multicentred study. Archives of Disease in Childhood Fetal
31 and Neonatal Edition. 2014; 99(4):F303-F308
- 32 309 Mudge DW, Tan KS, Miles R, Johnson DW, Campbell SB, Hawley CM et al. Intravenous versus
33 oral iron supplementation for correction of post-transplant anaemia in renal transplant
34 patients. BMC Nephrology. 2009; 10:14
- 35 310 Mudge DW, Tan K-S, Miles R, Johnson DW, Badve SV, Campbell SB et al. A randomized
36 controlled trial of intravenous or oral iron for posttransplant anemia in kidney
37 transplantation. Transplantation. 2012; 93(8):822-826
- 38 311 Muhammad N, Jamlos NF, Wahab NH, Alias NF, Ismail R, Hamzah N. Informed consent in
39 blood transfusion: Patients' perspectives. Vox Sanguinis. 2014; 107:216

- 1 312 Muller MCA, de Jonge E, Arbous MS, Spoelstra-de Man AME, Karakus A, Vroom MB et al.
2 Transfusion of fresh frozen plasma in non-bleeding ICU patients--TOPIC trial: study protocol
3 for a randomized controlled trial. *Trials*. 2011; 12:266
- 4 313 Munoz M, Breymann C, Garcia-Erce JA, Gomez-Ramirez S, Comin J, Bisbe E. Efficacy and safety
5 of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. *Vox*
6 *Sanguinis*. 2008; 94(3):172-183
- 7 314 Munoz M, Iglesias D, Garcia-Erce JA, Cuenca J, Herrera A, Martin-Montanez E et al. Utility and
8 cost of low-vacuum reinfusion drains in patients undergoing surgery for subcapital hip
9 fracture repair: a before and after cohort study. *Vox Sanguinis*. 2014; 106(1):83-91
- 10 315 Munoz M, Naveira E, Seara J, Palmer JH, Cuenca J, Garcia-Erce JA. Role of parenteral iron in
11 transfusion requirements after total hip replacement. A pilot study. *Transfusion Medicine*.
12 2006; 16(2):137-142
- 13 316 Munoz M, Ariza D, Campos A, Martin-Montanez E, Pavia J. The cost of post-operative shed
14 blood salvage after total knee arthroplasty: an analysis of 1,093 consecutive procedures.
15 *Blood Transfusion*. 2013; 11(2):260-271
- 16 317 Murphy GJ, Rogers CS, Lansdowne WB, Channon I, Alwair H, Cohen A et al. Safety, efficacy,
17 and cost of intraoperative cell salvage and autotransfusion after off-pump coronary artery
18 bypass surgery: a randomized trial. *Journal of Thoracic and Cardiovascular Surgery*. 2005;
19 130(1):20-28
- 20 318 Murphy MF, Casbard AC, Ballard S, Shulman IA, Heddle N, Aubuchon JP et al. Prevention of
21 bedside errors in transfusion medicine (PROBE-TM) study: a cluster-randomized, matched-
22 paired clinical areas trial of a simple intervention to reduce errors in the pretransfusion
23 bedside check. *Transfusion*. 2007; 47(5):771-780
- 24 319 Murphy S, Snyder E, Cable R, Slichter S, Strauss R, McCullough J. Transfusion of INTERCEPT
25 platelets vs. reference platelets at doses $\geq 3.0 \times 10^{11}$ results in comparable hemostasis and
26 platelet and RBC transfusion requirements. Results of the SPRINT trial. *Blood*. 2003; 102(11 Pt
27 1):815a
- 28 320 Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J et al. Platelet dose
29 consistency and its effect on the number of platelet transfusions for support of
30 thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with
31 amotosalen HCl and ultraviolet A light. *Transfusion*. 2006; 46(1):24-33
- 32 321 Naim A, Gollins JR, Reynolds C, Walls D. Examining knowledge and information seeking
33 behaviors towards blood transfusion among individuals with cancer. *Value in Health*. 2012;
34 15(4):A227
- 35 322 Naim A, Walls D, Gollins J, Reynolds C. Examining the patient-centered decision making
36 attributes towards blood transfusion among individuals with Chronic Kidney Disease (CKD).
37 *Pharmacotherapy*. 2011; 31(10):406e
- 38 323 Naim AB, Walls D, Gollins J, Reynolds C. Examining the role of caregiver towards blood
39 transfusion decisions among individuals with chronic kidney disease. *Blood*. 2011; 118(21)
- 40 324 Napolitano LM, Corwin HL. Efficacy of red blood cell transfusion in the critically ill. *Critical Care*
41 *Clinics*. 2004; 20(2):255-268

- 1 325 Nevo S, Fuller AK, Hartley E, Borinsky ME, Vogelsang GB. Acute bleeding complications in
2 patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion
3 triggers of 10×10^9 and 20×10^9 per L. *Transfusion*. 2007; 47(5):801-812
- 4 326 Ngaage DL, Bland JM. Lessons from aprotinin: is the routine use and inconsistent dosing of
5 tranexamic acid prudent? Meta-analysis of randomised and large matched observational
6 studies. *European Journal of Cardio-Thoracic Surgery*. 2010; 37(6):1375-1383
- 7 327 Ngo LT, Bruhn R, Custer B. Risk perception and its role in attitudes toward blood transfusion: a
8 qualitative systematic review. *Transfusion Medicine Reviews*. 2013; 27(2):119-128
- 9 328 Nicolai P, Leggetter PP, Glithero PR, Bhimarasetty CR. Autologous transfusion in
10 acetabuloplasty in children. *Journal of Bone and Joint Surgery British Volume*. 2004;
11 86(1):110-112
- 12 329 Nielsen K, Dahl B, Johansson PI, Henneberg SW, Rasmussen LS. Intraoperative transfusion
13 threshold and tissue oxygenation: a randomised trial. *Transfusion Medicine*. 2012; 22(6):418-
14 425
- 15 330 Noddeland H, Tollofsrud S, Svennevig J, Bentsen G, Brosstad F, Solheim B. Universal
16 solvent/detergent-treated fresh frozen plasma (Uniplas--rationale and clinical properties.
17 *Thrombosis Research*. 2002; 107 Suppl 1:S33-S37
- 18 331 Norol F, Duedari N, Kuentz M, Vernant JP. Comparison of different 'doses' of platelet
19 transfusion. *Blood*. 1995; 86(10 Suppl 1):353a
- 20 332 Novis DA, Miller KA, Howanitz PJ, Renner SW, Walsh MK, College of American Pathologists.
21 Audit of transfusion procedures in 660 hospitals. A College of American Pathologists Q-Probes
22 study of patient identification and vital sign monitoring frequencies in 16494 transfusions.
23 *Archives of Pathology and Laboratory Medicine*. 2003; 127(5):541-548
- 24 333 O'Hara J, Sprung J, Klein EA, Dilger JA, Domen RE, Piedmonte MR. Use of preoperative
25 autologous blood donation in patients undergoing radical retropubic prostatectomy. *Urology*.
26 1999; 54(1):130-134
- 27 334 Offierski CM, Gagne S, Bishop C. Efficacy of tranexamic acid for blood conservation in primary
28 total joint arthroplasty. *Transfusion Medicine*. 2013; 23:43
- 29 335 Ohsaka A, Abe K, Nakamura Y, Ohsawa T, Sugita S. Issuing of blood components dispensed in
30 syringes and bar code-based pretransfusion check at the bedside for pediatric patients.
31 *Transfusion*. 2009; 49(7):1423-1430
- 32 336 Oishi CS, D'Lima DD, Morris BA, Hardwick ME, Berkowitz SD, Colwell CWJ. Hemodilution with
33 other blood reinfusion techniques in total hip arthroplasty. *Clinical Orthopaedics and Related
34 Research*. 1997;(339):132-139
- 35 337 Orme J, Still D, Day R, Evans J, Perkins P. The experiences of patients undergoing blood
36 transfusion in a day hospice. *International Journal of Palliative Nursing*. 2013; 19(4):171-176
- 37 338 Otite F, Cai X, Bresette L, Henderson G, Sorond F, Feske S et al. PCC decreases time to surgery
38 but does not reduce mortality in warfarin-associated SDH. *Critical Care Medicine*. 2013; 41(12
39 Suppl 1):A114

- 1 339 Ozal E, Kuralay E, Bingol H, Cingoz F, Ceylan S, Tatar H. Does tranexamic acid reduce
2 desmopressin-induced hyperfibrinolysis? *Journal of Thoracic and Cardiovascular Surgery*.
3 2002; 123(3):539-543
- 4 340 Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H et al. Prothrombin complex
5 concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective
6 multinational clinical trial. *Journal of Thrombosis and Haemostasis*. 2008; 6(4):622-631
- 7 341 Pabinger I, Tiede A, Kalina U, Knaub S, Germann R, Ostermann H et al. Impact of infusion
8 speed on the safety and effectiveness of prothrombin complex concentrate: a prospective
9 clinical trial of emergency anticoagulation reversal. *Annals of Hematology*. 2010; 89(3):309-
10 316
- 11 342 Pagliaro P, Rebullia P. Transfusion recipient identification. *Vox Sanguinis*. 2006; 91(2):97-101
- 12 343 Pajoumand M, Erstad BL, Camamo JM. Use of epoetin alfa in critically ill patients. *Annals of*
13 *Pharmacotherapy*. 2004; 38(4):641-648
- 14 344 Palmieri TL, Lee T, O'Mara MS, Greenhalgh DG. Effects of a restrictive blood transfusion policy
15 on outcomes in children with burn injury. *Journal of Burn Care and Research*. United States
16 2007; 28(1):65-70
- 17 345 Palo R, Ali-Melkkila T, Hanhela R, Jantti V, Krusius T, Leppanen E et al. Development of
18 permanent national register of blood component use utilizing electronic hospital information
19 systems. *Vox Sanguinis*. 2006; 91(2):140-147
- 20 346 Panchmatia JR, Chegini S, Lobban C, Shah G, Stapleton C, Smallman JM et al. The routine use
21 of tranexamic acid in hip and knee replacements. *Bulletin of the NYU Hospital for Joint*
22 *Diseases*. United Kingdom 2012; 70(4):246-249
- 23 347 Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV. Topical tranexamic acid in total knee
24 replacement: a systematic review and meta-analysis. *Knee*. 2013; 20(5):300-309
- 25 348 Parker MJ. Randomised trial of blood transfusion versus a restrictive transfusion policy after
26 hip fracture surgery. *Injury*. 2013; 44(12):1916-1918
- 27 349 Parker RI. Transfusion in critically ill children: indications, risks, and challenges. *Critical Care*
28 *Medicine*. 2014; 42(3):675-690
- 29 350 Patanwala AE, Acquisto NM, Erstad BL. Prothrombin complex concentrate for critical
30 bleeding. *Annals of Pharmacotherapy*. 2011; 45(7-8):990-999
- 31 351 Patel JN, Spanyer JM, Smith LS, Huang J, Yakkanti MR, Malkani AL. Comparison of intravenous
32 versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study.
33 *Journal of Arthroplasty*. 2014; 29(8):1528-1531
- 34 352 Pedrazzoli P, Perotti C, Prada GA, Battaglia M, Noris P, Preti P et al. Autologous platelet
35 transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell
36 transplantation for high risk breast cancer. *Proceedings of the American Society of Clinical*
37 *Oncology*. 1997; 16:102a
- 38 353 Peitsidis P, Koukoulomati A. Tranexamic acid for the management of uterine fibroid tumors: a
39 systematic review of the current evidence. *World Journal of Clinical Cases*. 2014; 2(12):893-
40 898

- 1 354 Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU et al. A trial of
2 darbepoetin alfa in type 2 diabetes and chronic kidney disease. *New England Journal of*
3 *Medicine*. 2009; 361(21):2019-2032
- 4 355 Philcox DJ. Computer potential in transfusion laboratories. *IMLS Gazette*. 1987;
- 5 356 Pieracci FM, Henderson P, Rodney JRM, Holena DN, Genisca A, Ip I et al. Randomized, double-
6 blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of
7 infection during surgical critical illness. *Surgical Infections*. 2009; 10(1):9-19
- 8 357 Proctor MR, Meier P, Pereira L, McGowan F, Scharp L, Rogers G et al. Efficacy of tranexamic
9 acid on blood loss and transfusion rates in pediatric craniosynostosis surgery: A double blind
10 placebo controlled study. *Journal of Neurosurgery*. 2011; 115(2):A419-A420
- 11 358 Prokopchuk-Gauk O, Rosin M, Mycyk T, Lim H, Brose K. Topical application of tranexamic acid
12 to reduce post-operative bleeding in coronary artery bypass surgery. *Blood*. 2012; 120(21)
- 13 359 Pundir V, Pundir J, Georgalas C, Fokkens WJ. Role of tranexamic acid in endoscopic sinus
14 surgery - a systematic review and meta-analysis. *Rhinology*. 2013; 51(4):291-297
- 15 360 Puroonen C, Libby E. Reversal of excessive warfarin anticoagulation with fresh frozen plasma: a
16 study of the turnaround time for plasma administration from ordering to infusion.
17 *Haemophilia*. 2009; 15(2):627
- 18 361 Quillen K, Murphy K. Quality improvement to decrease specimen mislabeling in transfusion
19 medicine. *Archives of Pathology and Laboratory Medicine*. 2006; 130(8):1196-1198
- 20 362 Rajesparan K, Biant LC, Ahmad M, Field RE. The effect of an intravenous bolus of tranexamic
21 acid on blood loss in total hip replacement. *Journal of Bone and Joint Surgery British Volume*.
22 2009; 91(6):776-783
- 23 363 Rao M, Caceres J, Timothy AD, Cotto L, Garcia SR. Implementation of an educational
24 intervention and an electronic decision support model with computerized order entry to
25 reduce inappropriate red blood cell transfusions. *Journal of General Internal Medicine*. 2013;
26 28:S103
- 27 364 Rao VK, Dyga R, Bartels C, Waters JH. A cost study of postoperative cell salvage in the setting
28 of elective primary hip and knee arthroplasty. *Transfusion*. 2012; 52(8):1750-1760
- 29 365 Razzaghi A, Barkun AN. Platelet transfusion threshold in patients with upper gastrointestinal
30 bleeding: a systematic review. *Journal of Clinical Gastroenterology*. 2012; 46(6):482-486
- 31 366 Rebullà P. Interim report from the platelet transfusion trigger trial (PTTT): a prospective
32 controlled study on bleeding risk in acute myeloblastic leukemia (AML) patients randomized
33 to be transfused at ≤ 10 versus $\leq 20 \times 10^9/L$ platelets. *Blood*. 1996; 88(10):443a
- 34 367 Rebullà P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G et al. The threshold for
35 prophylactic platelet transfusions in adults with acute myeloid leukemia. *Gruppo Italiano*
36 *Malattie Ematologiche Maligne dell'Adulto*. *New England Journal of Medicine*. 1997;
37 337(26):1870-1875
- 38 368 Reim D, Kim YW, Nam BH, Kim MJ, Yook JH, Park YK et al. FAIRY: a randomized controlled
39 patient-blind phase III study to compare the efficacy and safety of intravenous ferric

- 1 carboxymaltose (Ferinject) to placebo in patients with acute isovolemic anemia after
2 gastrectomy - study protocol for a randomized controlled trial. *Trials*. 2014; 15:111
- 3 369 Renner SW, Howanitz PJ, Bachner P. Wristband identification error reporting in 712 hospitals:
4 a College of American Pathologists' Q-Probes study of quality issues in transfusion practice.
5 *Archives of Pathology and Laboratory Medicine*. 1993; 117(6):573-577
- 6 370 Rentas FJ, Clark PA. Blood type discrepancies on military identification cards and tags: a
7 readiness concern in the U.S. Army. *Military Medicine*. 1999; 164(11):785-787
- 8 371 Riley W, Smalley B, Pulkrabek S, Clay ME, McCullough J. Using lean techniques to define the
9 platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion
10 strategies. *Transfusion*. 2012; 52(9):1957-1967
- 11 372 Risch A, Dorscheid E, Stein G, Seyfert UT, Grundmann U. The effect of aprotinin and
12 tranexamic acid on fibrinolysis and thrombin generation during cardiopulmonary bypass. *Der*
13 *Anaesthesist*. 2000; 49(4):279-285
- 14 373 Rosland RG, Hagen MU, Haase N, Holst LB, Plambech M, Madsen KR et al. Red blood cell
15 transfusion in septic shock - clinical characteristics and outcome of unselected patients in a
16 prospective, multicentre cohort. *Scandinavian Journal of Trauma, Resuscitation and*
17 *Emergency Medicine*. 2014; 22:14
- 18 374 Rothschild JM, McGurk S, Honour M, Fiskio J, Avorn J, Cook EF et al. The impact of
19 computerized decision support guidelines on transfusion practice. *Transfusion*. 2004;
20 44(s1):3A
- 21 375 Rouette J, Trottier H, Ducruet T, Beaunoyer M, Lacroix J, Tucci M. Red blood cell transfusion
22 threshold in postsurgical pediatric intensive care patients: a randomized clinical trial. *Annals*
23 *of Surgery*. 2010; 251(3):421-427
- 24 376 Rowlands M, Forward DP, Sahota O, Moppett IK. The effect of intravenous iron on
25 postoperative transfusion requirements in hip fracture patients: study protocol for a
26 randomized controlled trial. *Trials*. 2013; 14:288
- 27 377 Rybo G, Westerberg H. The effect of tranexamic acid (AMCA) on postoperative bleeding after
28 conization. *Acta Obstetrica Et Gynecologica Scandinavica*. 1972; 51(4):347-350
- 29 378 Sahin DG, Akay OM, Karagulle M, Gunduz E, Gulbas Z. Thromboelastographic follow-up of
30 prophylactic thrombocyte transfusion. *Blood*. 2013; 122(21)
- 31 379 Sandler SG, Langeberg A, Debandi L, Gibble J, Wilson C, Feldman CL. Radiofrequency
32 identification technology can standardize and document blood collections and transfusions.
33 *Transfusion*. 2007; 47(5):763-770
- 34 380 Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C. Prospective
35 monitoring of plasma and platelet transfusions in a large teaching hospital results in
36 significant cost reduction. *Transfusion*. 2010; 50(2):487-492
- 37 381 Sasanuma H, Sekiya H, Takatoku K, Takada H, Sugimoto N, Hoshino Y. Efficient strategy for
38 controlling postoperative hemorrhage in total knee arthroplasty. *Knee Surgery, Sports*
39 *Traumatology, Arthroscopy*. 2011; 19(6):921-925

- 1 382 Savvidou C, Chatziioannou SN, Pilichou A, Pneumaticos SG. Efficacy and cost-effectiveness of
2 cell saving blood autotransfusion in adult lumbar fusion. *Transfusion Medicine*. 2009;
3 19(4):202-206
- 4 383 Schiffer CA, Aisner J, Wiernik PH. Clinical experience with transfusion of cryopreserved
5 platelets. *British Journal of Haematology*. 1976; 34(3):377-385
- 6 384 Schiffer CA, Buchholz DH, Aisner J. Frozen autologous platelets in the supportive care of
7 patients with leukemia. *Transfusion*. 1976; 16(4):321-329
- 8 385 Schnurr C, Csecsei G, Eysel P, Konig DP. The effect of computer navigation on blood loss and
9 transfusion rate in TKA. *Orthopedics*. 2010; 33(7):474
- 10 386 Schouten ES, van de Pol AC, Schouten ANJ, Turner NM, Jansen NJG, Bollen CW. The effect of
11 aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in
12 major pediatric surgery: a meta-analysis. *Pediatric Critical Care Medicine*. 2009; 10(2):182-190
- 13 387 Schulmeister L. Patient misidentification in oncology care. *Clinical Journal of Oncology*
14 *Nursing*. 2008; 12(3):495-498
- 15 388 Sensebe L, Giraudeau B, Bardiaux L, Deconinck E, Schmidt A, Bidet ML et al. The efficiency of
16 transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of
17 a prospective, randomized, open, blinded end point (PROBE) study. *Blood*. 2005; 105(2):862-
18 864
- 19 389 Sezik S, Aksay E, Kilic TY. The effect of fresh frozen plasma transfusion on international
20 normalized ratio in emergency department patients. *Journal of Emergency Medicine*. 2014;
21 47(5):596-600
- 22 390 Shah A, Stanworth SJ, McKechnie S. Evidence and triggers for the transfusion of blood and
23 blood products. *Anaesthesia*. 2015; 70 Suppl 1:10-e3
- 24 391 Shantikumar S, Patel S, Handa A. The role of cell salvage autotransfusion in abdominal aortic
25 aneurysm surgery. *European Journal of Vascular and Endovascular Surgery*. 2011; 42(5):577-
26 584
- 27 392 Shehata N, Burns LA, Nathan H, Hebert P, Hare GMT, Fergusson D et al. A randomized
28 controlled pilot study of adherence to transfusion strategies in cardiac surgery. *Transfusion*.
29 2012; 52(1):91-99
- 30 393 Shen J, Liang J, Chua S. Does intraoperative cell salvage system effectively decrease the need
31 for allogeneic transfusions in scoliotic patients undergoing posterior spinal fusion: A
32 prospective randomized study. *European Spine Journal*. 2013; 22(5 Suppl 1):S758-S759
- 33 394 Shimizu K, Toda Y, Iwasaki T, Takeuchi M, Morimatsu H, Egi M et al. Effect of tranexamic acid
34 on blood loss in pediatric cardiac surgery: a randomized trial. *Journal of Anesthesia*. 2011;
35 25(6):823-830
- 36 395 Shimpo H, Mizumoto T, Tanaka K, Yada I, Kusagawa M. Recombinant human erythropoietin
37 (EPO) in pediatric open heart surgery. *Japanese Journal of Artificial Organs*. 1994; 23(3):956-
38 959
- 39 396 Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, Grimshaw J. The effects of on-
40 screen, point of care computer reminders on processes and outcomes of care. *Cochrane*

- 1 Database of Systematic Reviews. 2009; Issue 3:CD001096.
2 DOI:10.1002/14651858.CD001096.pub2
- 3 397 Shulman G, Solanki DR, Hadjipavlou A. Augmented autologous transfusions in major
4 reconstructive spine surgery. *Journal of Clinical Apheresis*. 1998; 13(2):62-68
- 5 398 Silva LLM, Andres AJB, Senger R, Stuermer R, Godoy MCM, Correa EFM et al. Impact of
6 autologous blood transfusion on the use of pack of red blood cells in coronary artery bypass
7 grafting surgery. *Brazilian Journal of Cardiovascular Surgery*. 2013; 28(2):183-189
- 8 399 Sinclair KC, Clarke HD, Noble BN. Blood management in total knee arthroplasty: a comparison
9 of techniques. *Orthopedics*. 2009; 32(1):19
- 10 400 Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M et al. Correction of anemia with
11 epoetin alfa in chronic kidney disease. *New England Journal of Medicine*. 2006; 355(20):2085-
12 2098
- 13 401 Singh AK, Fishbane S. The optimal hemoglobin in dialysis patients- a critical review. *Seminars*
14 *in Dialysis*. 2008; 21(1):1-6
- 15 402 Singh J, Ballal MS, Mitchell P, Denn PG. Effects of tranexamic acid on blood loss during total
16 hip arthroplasty. *Journal of Orthopaedic Surgery*. 2010; 18(3):282-286
- 17 403 Slichter SJ, Kaufman RM, Assmann SF, Brecher ME, Gernsheimer T, Hillyer CD et al. Effects of
18 prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). *Blood*. 2009;
19 112(11):111-112
- 20 404 Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet
21 dose on bleeding risk in thrombocytopenic patients. *Journal of Clinical Apheresis*. 2006;
22 21(1):78-84
- 23 405 Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ et al. Factors affecting
24 posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals
25 in thrombocytopenic patients. *Blood*. 2005; 105(10):4106-4114
- 26 406 Slight RD, O'Donohoe P, Fung AKY, Alonzi C, McClelland DBL, Mankad PS. Rationalizing blood
27 transfusion in cardiac surgery: the impact of a red cell volume-based guideline on blood usage
28 and clinical outcome. *Vox Sanguinis*. 2008; 95(3):205-210
- 29 407 Slover J, Bosco J. Cost analysis of use of tranexamic acid to prevent major bleeding
30 complications in hip and knee arthroplasty surgery. *American Journal of Orthopedics*. 2014;
31 43(10):E217-E220
- 32 408 Smith AH, Laussen PC. Cardiac critical care: What really makes a difference. *Current Opinion in*
33 *Pediatrics*. 2013; 25(5):567-573
- 34 409 Smith AF, Casey K, Wilson J. Wristbands as aids to reduce misidentification : an
35 ethnographically guided task analysis. *International Journal for Quality in Health Care*. 2011;
36 23(5):590-599
- 37 410 So-Osman C. Cost effectiveness of patient blood management methods. *Vox Sanguinis*. 2014;
38 107:11-12

- 1 411 So-Osman C, Nelissen R, Slaa R, Coene L, Brand R, Brand A. A randomized comparison of
2 transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells.
3 *Vox Sanguinis*. 2010; 98(1):56-64
- 4 412 So-Osman C, Nelissen R, Brand R, Faber F, Slaa RT, Stiggelbout A et al. The impact of a
5 restrictive transfusion trigger on post-operative complication rate and well-being following
6 elective orthopaedic surgery: a post-hoc analysis of a randomised study. *Blood Transfusion*.
7 2013; 11(2):289-295
- 8 413 So-Osman C, Nelissen RGHH, Koopman-van Gemert AWMM, Kluyver E, Poll RG, Onstenk R et al.
9 Patient blood management in elective total hip- and knee-replacement surgery (part 1): a
10 randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives
11 using a restrictive transfusion policy in erythropoietin-eligible patients. *Anesthesiology*. 2014;
12 120(4):839-851
- 13 414 Solbeck S, Ostrowski SR, Johansson PI. A review of the clinical utility of INR to monitor and
14 guide administration of prothrombin complex concentrate to orally anticoagulated patients.
15 *Thrombosis Journal*. 2012; 10(1):5
- 16 415 Solomon J, Bofenkamp T, Fahey JL, Chillar RK, Beutel E. Platelet prophylaxis in acute non-
17 lymphoblastic leukaemia. *Lancet*. 1978; 1(8058):267
- 18 416 Song G, Yang P, Hu J, Zhu S, Li Y, Wang Q. The effect of tranexamic acid on blood loss in
19 orthognathic surgery: a meta-analysis of randomized controlled trials. *Oral Surgery, Oral
20 Medicine, Oral Pathology and Oral Radiology*. 2013; 115(5):595-600
- 21 417 Song G, Yang P, Zhu S, Luo E, Feng G, Hu J et al. Tranexamic Acid reducing blood transfusion in
22 children undergoing craniostyostosis surgery. *Journal of Craniofacial Surgery*. 2013;
23 24(1):299-303
- 24 418 Sowade B, Sowade O, Mocks J, Franke W, Warnke H. The safety of treatment with
25 recombinant human erythropoietin in clinical use: a review of controlled studies.
26 *International Journal of Molecular Medicine*. 1998; 1(2):303-314
- 27 419 Specchiulli F, Rendina M, Berardi M. Reduction of blood loss using tranexamic acid in total
28 knee and hip arthroplasties. *Journal of Orthopaedics and Traumatology*. 2011; 12:S87
- 29 420 Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DBL, Murphy MF. Is fresh frozen plasma
30 clinically effective? A systematic review of randomized controlled trials. *British Journal of
31 Haematology*. 2004; 126(1):139-152
- 32 421 Stanworth SJ, Brunskill SJ, Hyde CJ, Murphy MF, McClelland DBL. Appraisal of the evidence for
33 the clinical use of FFP and plasma fractions. *Best Practice and Research Clinical Haematology*.
34 2006; 19(1):67-82
- 35 422 Stanworth SJ, Hyde C, Heddle N, Rebullia P, Brunskill S, Murphy MF. Prophylactic platelet
36 transfusion for haemorrhage after chemotherapy and stem cell transplantation. *Cochrane
37 Database of Systematic Reviews*. 2004; Issue 4:CD004269
- 38 423 Stanworth SJ, Hyde CJ, Murphy MF. Evidence for indications of fresh frozen plasma.
39 *Transfusion Clinique Et Biologique*. 2007; 14(6):551-556

- 1 424 Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll D. A national study of
2 plasma use in critical care: Clinical indications, dose and effect on prothrombin time. *Critical*
3 *Care*. 2011; 15(2):R108
- 4 425 Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of
5 coagulation tests and clinical coagulopathy. *Hematology*. 2007;179-186
- 6 426 Stanworth SJ, Dyer C, Choo L, Bakrania L, Coppelstone A, Llewelyn C et al. Do all patients with
7 hematologic malignancies and severe thrombocytopenia need prophylactic platelet
8 transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis)
9 to assess the effectiveness of prophylactic platelet transfusions. *Transfusion Medicine*
10 *Reviews*. 2010; 24(3):163-171
- 11 427 Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L et al. A no-prophylaxis platelet-
12 transfusion strategy for hematologic cancers. *New England Journal of Medicine*. 2013;
13 368(19):1771-1780
- 14 428 Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B et al. Influence of
15 prothrombin complex concentrates on plasma coagulation in critically ill patients. *Intensive*
16 *Care Medicine*. 1999; 25(10):1105-1110
- 17 429 Steffens I, Harrison JF, Taylor CPF. A dose response study of platelet transfusion: comparison
18 between triple dose apheresis platelet transfusion and three split standard transfusions. 7th
19 Congress of the European Hematology Association. 2002;
- 20 430 Stevens LE, Clemmer TP, Laub RM, Miya F, Robbins L. Fibrinogen in severe sepsis. *Surgery,*
21 *Gynecology and Obstetrics*. 1986; 162(3):222-228
- 22 431 Strippoli Giovanni FM, Navaneethan SD, Craig JC, Palmer SC. Haemoglobin and haematocrit
23 targets for the anaemia of chronic kidney disease. *Cochrane Database of Systematic Reviews*.
24 2006; Issue 4:CD003967. DOI:10.1002/14651858.CD003967.pub2
- 25 432 Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use
26 of tranexamic acid in total hip replacement. *Journal of Bone and Joint Surgery British Volume*.
27 2011; 93(1):39-46
- 28 433 Sun SL, Tian JH, Yang KH, Gao M, Liu R, Li J. Intraoperative blood salvage for penetrating
29 abdominal and thoracic trauma. *Cochrane Database of Systematic Reviews*. 2008; Issue
30 4:CD007379
- 31 434 Taj N, Firdous A, Akhtar N, Chaudhary MH, Sarah, Bajwa Z et al. Efficacy of tranexamic acid in
32 reducing blood loss during and after Cesarean section. *Rawal Medical Journal*. 2014;
33 39(3):311-313
- 34 435 Tan J, Chen H, Liu Q, Chen C, Huang W. A meta-analysis of the effectiveness and safety of
35 using tranexamic acid in primary unilateral total knee arthroplasty. *Journal of Surgical*
36 *Research*. 2013; 184(2):880-887
- 37 436 Tay J, Tinmouth A, Fergusson D, Allan D. Transfusion of red cells in hematopoietic stem cell
38 transplantation (TRIST): study protocol for a randomized controlled trial. *Trials*. 2011; 12:207
- 39 437 Teitel J, Rockman G, Mazer CD, Pavenski K. Hypofibrinogenemia and cryoprecipitate use in on-
40 pump cardiac surgery. *Journal of Thrombosis and Haemostasis*. 2011; 9:476

- 1 438 Thomas P, Evans C. An identity crisis? Aspects of patient misidentification. *Clinical Risk*. 2004;
2 10(1):18-22
- 3 439 Thomassen BJW, Pilot P, Grohs JG, Holen K, Bisbe E, Poolman RW. A prospective, randomized,
4 controlled trial of retransfusion of intra-operatively collected filtered whole blood in total hip
5 surgery with the Sangvia Blood Reinfusion System. *Transfusion Alternatives in Transfusion*
6 *Medicine*. 2011; 12(1):28
- 7 440 Tiehen A, Swanson S. Implementing the ISBT 128 labeling standard in a transfusion service.
8 *MLO: Medical Laboratory Observer*. 1998; 30(5):18
- 9 441 Tinegate H, Grant-Casey J, Hennem S, Kilner M, Rowley M, Seeney F et al. Is cryoprecipitate
10 transfusion guided by fibrinogen level? A survey of use in three english regions. *Transfusion*
11 *Medicine*. 2011; 21:4
- 12 442 Tinmouth A, Chatelain E, Fergusson D, McIntyre L, Giulivi A, Hebert P. A randomized
13 controlled trial of high and standard dose frozen plasma transfusions in critically ill patients.
14 *Transfusion*. 2008; 48(Suppl):26A-27A
- 15 443 Tinmouth A, Kotchetkova N, Tomlinson G, Crump M, Brandwein J, Tannock I et al. A
16 randomized phase II trial of low dose and standard dose platelet transfusions during induction
17 therapy for acute leukemia or autologous stem cell transplantation. *Vox Sanguinis*. 2002; 83:8
- 18 444 Tinmouth A, Tannock IF, Crump M, Tomlinson G, Brandwein J, Minden M et al. Low-dose
19 prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor
20 cell transplant and patients with acute leukemia: a randomized controlled trial with a
21 sequential Bayesian design. *Transfusion*. 2004; 44(12):1711-1719
- 22 445 Tinmouth AT, Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A
23 review of the literature. *Transfusion Medicine Reviews*. 2003; 17(3):181-193
- 24 446 Toda Y, Iwasaki T, Shimizu K, Yamaoka M, Kawade K, Kanazawa T et al. Relationship between
25 serum concentration of tranexamic acid and blood loss in paediatric cardiac surgery. *Applied*
26 *Cardiopulmonary Pathophysiology*. 2013; 17(2):207-208
- 27 447 Tolich DJ. Patient descriptions of receiving a blood transfusion. *Transfusion*. 2010;
28 50(11):2516
- 29 448 Tollofsrud S, Noddeland H, Svennevig JL, Bentsen G, Mollnes TE, Solheim BG. Universal fresh
30 frozen plasma (Uniplas): a safe product in open-heart surgery. *Intensive Care Medicine*. 2003;
31 29(10):1736-1743
- 32 449 Tran DHD, Wong GTC, Chee YE, Irwin MG. Effectiveness and safety of erythropoiesis-
33 stimulating agent use in the perioperative period. *Expert Opinion on Biological Therapy*. 2014;
34 14(1):51-61
- 35 450 Trimble AS, Osborn JJ, Kerth WJ, Gerbode F. The prophylactic use of fresh frozen plasma after
36 extracorporeal circulation. *Journal of Thoracic and Cardiovascular Surgery*. 1964; 48:314-316
- 37 451 Tripodi A, Chantarangkul V, Primignani M, Clerici M, Dell'era A, Aghemo A et al. Thrombin
38 generation in plasma from patients with cirrhosis supplemented with normal plasma:
39 considerations on the efficacy of treatment with fresh-frozen plasma. *Internal and Emergency*
40 *Medicine*. 2012; 7(2):139-144

- 1 452 Triulzi D, Assmann S, Strauss RG, Ness PM, Hess JR, Granger S et al. Characteristics of
2 transfused platelets do not affect bleeding outcomes in hypoproliferative thrombocytopenia.
3 Blood. 2009; 114(22)
- 4 453 Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM et al. The impact of
5 platelet transfusion characteristics on posttransfusion platelet increments and clinical
6 bleeding in patients with hypoproliferative thrombocytopenia. Blood. 2012; 119(23):5553-
7 5562
- 8 454 Tuttle JR, Ritterman SA, Cassidy DB, Anazonwu WA, Froehlich JA, Rubin LE. Cost benefit
9 analysis of topical tranexamic acid in primary total hip and knee arthroplasty. Journal of
10 Arthroplasty. 2014; 29(8):1512-1515
- 11 455 Twiss J, McKenna SP, Crawford SR, Wilburn JN, Loth K, Mufti GJ. Myelodysplasia (MDS)
12 patients' experiences with blood transfusions. Blood. 2011; 118(21)
- 13 456 Uriz MJ, Antelo ML, Zalba S, Ugalde N, Pena E, Corcoz A. Improved traceability and transfusion
14 safety with a new portable computerised system in a hospital with intermediate transfusion
15 activity. Blood Transfusion. 2011; 9(2):172-181
- 16 457 Urwyler N, Trelle S, Theiler L, Juni P, Staub LP, Luyet C et al. Does point of care prothrombin
17 time measurement reduce the transfusion of fresh frozen plasma in patients undergoing
18 major surgery? The POC-OP randomized-controlled trial. Trials. 2009; 10:107
- 19 458 Vacharaksa K, Prakanrattana U, Suksompong S, Chumpathong S. Tranexamic acid as a means
20 of reducing the need for blood and blood component therapy in children undergoing open
21 heart surgery for congenital cyanotic heart disease. Journal of the Medical Association of
22 Thailand. 2002; 85 Suppl 3:S904-S909
- 23 459 Valenstein PN, Sirota RL. Identification errors in pathology and laboratory medicine. Clinics in
24 Laboratory Medicine. 2004; 24(4):979-996
- 25 460 Valentino LA. Assessing the benefits APCC prophylaxis in hemophilia patients with inhibitors.
26 Journal of Thrombosis and Haemostasis. 2009; 7(S2):824
- 27 461 Valeri CR, Crowley JP, Loscalzo J. The red cell transfusion trigger: has a sin of commission now
28 become a sin of omission? Transfusion. 1998; 38(6):602-610
- 29 462 Van Loo A, Vanholder R, Bernaert P, De Roose J, Lameire N. Recombinant human
30 erythropoietin corrects anaemia during the first weeks after renal transplantation: a
31 randomized prospective study. Nephrology, Dialysis, Transplantation. 1996; 11(9):1815-1821
- 32 463 van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H et al.
33 Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen
34 inactivation treatment: the euroSPRITE trial. Blood. 2003; 101(6):2426-2433
- 35 464 Varga C, Al-Touri S, Papadoukakis S, Caplan S, Kahn S, Blostein M. The effectiveness and safety
36 of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of
37 warfarin. Transfusion. 2013; 53(7):1451-1450
- 38 465 Vela E, Alvarez JC, Vollmer I, Maiques J, Puig L, Santiveri FX. Tranexamic acid reduces blood
39 transfusion without increases in thrombotic complications in joint replacement surgery.
40 European Journal of Anaesthesiology. 2012; 29:96

- 1 466 Verghese SG. Elective fresh frozen plasma in the critically ill: what is the evidence? *Critical*
2 *Care and Resuscitation*. 2008; 10(3):264-268
- 3 467 Vetter TR, Adhami LF, Porterfield JRJ, Marques MB. Perceptions about blood transfusion: a
4 survey of surgical patients and their anesthesiologists and surgeons. *Anesthesia and*
5 *Analgesia*. 2014; 118(6):1301-1308
- 6 468 Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M et al. A comparison of
7 conservative and aggressive transfusion regimens in the perioperative management of sickle
8 cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. *New England*
9 *Journal of Medicine*. 1995; 333(4):206-213
- 10 469 Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who
11 refuse blood? The experience with Jehovah's Witnesses. *Transfusion*. 1994; 34(5):396-401
- 12 470 Vigna-Taglianti F, Basso L, Rolfo P, Brambilla R, Vaccari F, Lanci G et al. Tranexamic acid for
13 reducing blood transfusions in arthroplasty interventions: a cost-effective practice. *European*
14 *Journal of Orthopaedic Surgery and Traumatology*. 2014; 24(4):545-551
- 15 471 Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex
16 concentrate for warfarin reversal: does it matter? *Thrombosis Research*. 2012; 130(6):833-
17 840
- 18 472 Wali YA, al Okbi H, al Abri R. A comparison of two transfusion regimens in the perioperative
19 management of children with sickle cell disease undergoing adenotonsillectomy. *Pediatric*
20 *Hematology and Oncology*. 2003; 20(1):7-13
- 21 473 Walpoth B, Galliker B, Spirig P, Haeberli A, Rosenmund A, Althaus U et al. Use of epoetin alfa
22 in autologous blood donation programs for patients scheduled for elective cardiac surgery.
23 *Seminars in Hematology*. 1996; 33(2 Suppl 2):75-77
- 24 474 Walsh T. FFP use in ITU. *Transfusion Medicine*. 2011; 21:10
- 25 475 Walsh TS, Boyd JA, Watson D, Hope D, Lewis S, Krishan A et al. Restrictive versus liberal
26 transfusion strategies for older mechanically ventilated critically ill patients: a randomized
27 pilot trial. *Critical Care Medicine*. 2013; 41(10):2354-2363
- 28 476 Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A et al. Safety and cost
29 effectiveness of a 10 x 10⁹/L trigger for prophylactic platelet transfusions compared with the
30 traditional 20 x 10⁹/L trigger: a prospective comparative trial in 105 patients with acute
31 myeloid leukemia. *Blood*. 1998; 91(10):3601-3606
- 32 477 Wandt H, Frank M, Link H, Schneider C, Brack N, Daoud A et al. The 10/NL trigger for
33 prophylactic platelet transfusion in AML: a prospective comparative multicenter study. *Annals*
34 *of Hematology*. 1995; 70 Suppl 1:A140
- 35 478 Wandt H, Schaefer-Eckart K, Wendelin K, Rottmann M, Thalheimer M, Schubert MS et al. A
36 therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible
37 and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised
38 study after high-dose chemotherapy and PBSCT. *Bone Marrow Transplantation*. 2009;
39 43(Suppl 1s):S23
- 40 479 Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M et al. Therapeutic
41 platelet transfusion versus routine prophylactic transfusion in patients with haematological

- 1 malignancies: an open-label, multicentre, randomised study. *Lancet*. 2012; 380(9850):1309-
2 1316
- 3 480 Wang G, Bainbridge D, Martin J, Cheng D. The efficacy of an intraoperative cell saver during
4 cardiac surgery: a meta-analysis of randomized trials. *Anesthesia and Analgesia*. 2009;
5 109(2):320-330
- 6 481 Wang J, Bao YX, Bai M, Zhang YG, Xu WD, Qi XS. Restrictive vs liberal transfusion for upper
7 gastrointestinal bleeding: a meta-analysis of randomized controlled trials. *World Journal of*
8 *Gastroenterology*. 2013; 19(40):6919-6927
- 9 482 Wardrop D, Estcourt L, Brunskill SJ, Doree C, Trivella M, Stanworth S et al. Anti-fibrinolytics
10 (lysine analogues) for the prevention of bleeding in patients with hematological disorders: A
11 systematic review. *Blood*. 2012; 120(21)
- 12 483 Warmuth M, Mad P, Wild C. Systematic review of the efficacy and safety of fibrinogen
13 concentrate substitution in adults. *Acta Anaesthesiologica Scandinavica*. 2012; 56(5):539-548
- 14 484 Washington B, Liakonis C, Pagnanelli R, Salerno C, Barnett L, Lonquist J et al. Post-operative
15 cell salvage reduces allogeneic RBC transfusion rate in patients undergoing cardiovascular
16 surgery. *Transfusion*. 2009; 49(10):2257-2258
- 17 485 Watanabe Y, Fuse K, Naruse Y, Kobayashi T, Yamamoto S, Konishi H et al. Subcutaneous use of
18 erythropoietin in heart surgery. *Annals of Thoracic Surgery*. 1992; 54(3):479-4
- 19 486 Waters JH. How to implement a hospital-based blood management program. *Vox Sanguinis*.
20 2012; 103:38
- 21 487 Waters JH, Yazer M, Chen YF, Kloke J. Blood salvage and cancer surgery: a meta-analysis of
22 available studies. *Transfusion*. 2012; 52(10):2167-2173
- 23 488 Weber EWG, Slappendel R, Hemon Y, Mahler S, Dalen T, Rouwet E et al. Effects of epoetin alfa
24 on blood transfusions and postoperative recovery in orthopaedic surgery: the European
25 Epoetin Alfa Surgery Trial (EEST). *European Journal of Anaesthesiology*. 2005; 22(4):249-257
- 26 489 Webert KE, Cook RJ, Couban S, Carruthers J, Lee KA, Blajchman MA et al. A multicenter pilot-
27 randomized controlled trial of the feasibility of an augmented red blood cell transfusion
28 strategy for patients treated with induction chemotherapy for acute leukemia or stem cell
29 transplantation. *Transfusion*. 2008; 48(1):81-91
- 30 490 Weltert L, Nardella S, Rondinelli MB, Pierelli L, De Paulis R. Reduction of allogeneic red blood
31 cell usage during cardiac surgery by an integrated intra- and postoperative blood salvage
32 strategy: results of a randomized comparison. *Transfusion*. 2013; 53(4):790-797
- 33 491 Wenz B, Burns ER. Improvement in transfusion safety using a new blood unit and patient
34 identification system as part of safe transfusion practice. *Transfusion*. 1991; 31(5):401-403
- 35 492 White L, Friedman M, Nichols C, Menzin J, Hoesche J, Jones C. Failure to correct international
36 normalized ratio following fresh frozen plasma administration among patients with
37 anticoagulant-related major bleeding in clinical practice. *Annals of Emergency Medicine*.
38 2011; 58(4 Suppl 1):S278

- 1 493 Whyte R, Kirpalani H. Low versus high haemoglobin concentration threshold for blood
2 transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane
3 Database of Systematic Reviews. 2011; Issue 11:CD000512
- 4 494 Wickham S. Thinking outside the box. Blood, barcodes and normalisation. Practising Midwife.
5 2006; 9(9):43
- 6 495 Wickham V, Miedema F, Gamerdinger K, DeGooyer J. Bar-coded patient ID: review an
7 organizational approach to vendor selection. Nursing Management. 2006; 37(12):22
- 8 496 Wikkelsø A, Lunde J, Johansen M, Stensballe J, Wetterslev J, Møller AM et al. Fibrinogen
9 concentrate in bleeding patients. Cochrane Database of Systematic Reviews. 2013; Issue
10 8:CD008864. DOI:10.1002/14651858.CD008864.pub2
- 11 497 Willems A, Harrington K, Lacroix J, Biarent D, Joffe AR, Wensley D et al. Comparison of two
12 red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis. Critical Care
13 Medicine. 2010; 38(2):649-656
- 14 498 Willems A, Van Lerberghe C, Gonsette K, De Ville A, Melot C, Hardy J-F et al. The indication for
15 perioperative red blood cell transfusions is a predictive risk factor for severe postoperative
16 morbidity and mortality in children undergoing cardiac surgery. European Journal of Cardio-
17 Thoracic Surgery. 2014; 45(6):1050-1057
- 18 499 Williams D, Smith L, Langkamer VG. A randomised prospective study of post operative blood
19 salvage with autologous retransfusion in primary total hip replacement. Journal of Bone and
20 Joint Surgery British Volume. 2009; 91-B(Suppl I):102-10d
- 21 500 Williamson LM, Llewelyn CA, Fisher NC, Allain JP, Bellamy MC, Baglin TP et al. A randomized
22 trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of
23 liver disease and liver transplantation. Transfusion. 1999; 39(11-12):1227-1234
- 24 501 Yagi M, Hasegawa J, Nagoshi N, Iizuka S, Kaneko S, Fukuda K et al. Does the intraoperative
25 tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of
26 adolescent idiopathic scoliosis? Spine. 2012; 37(21):E1336-E1342
- 27 502 Yang B, Li H, Wang D, He X, Zhang C, Yang P. Systematic review and meta-analysis of
28 perioperative intravenous tranexamic acid use in spinal surgery. PloS One. 2013; 8(2):e55436
- 29 503 Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-frozen plasma clinically
30 effective? An update of a systematic review of randomized controlled trials (CME).
31 Transfusion. 2012; 52(8):1673-1686
- 32 504 Yang Y, Li H, Li B, Wang Y, Jiang S, Jiang L. Efficacy and safety of iron supplementation for the
33 elderly patients undergoing hip or knee surgery: a meta-analysis of randomized controlled
34 trials. Journal of Surgical Research. 2011; 171(2):e201-e207
- 35 505 Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss
36 in total knee arthroplasty: a meta-analysis. Journal of Bone and Joint Surgery American
37 Volume. 2012; 94(13):1153-1159
- 38 506 Yassen K, Bellamy MC, Sadek SA, Webster NR. Tranexamic acid reduces blood loss during
39 orthotopic liver transplantation. Clinical Transplantation. 1993; 7(5):453-458

- 1 507 Yazicioglu L, Eryilmaz S, Sirlak M, Inan MB, Aral A, Tasoş R et al. Recombinant human
2 erythropoietin administration in cardiac surgery. *Journal of Thoracic and Cardiovascular*
3 *Surgery*. 2001; 122(4):741-745
- 4 508 Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD. Role of fresh frozen plasma infusion
5 in correction of coagulopathy of chronic liver disease: a dual phase study. *American Journal of*
6 *Gastroenterology*. 2003; 98(6):1391-1394
- 7 509 Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, Thinkamrop B, Phuenpathom N,
8 Lumbiganon P. Tranexamic acid for patients with traumatic brain injury: a randomized,
9 double-blinded, placebo-controlled trial. *BMC Emergency Medicine*. 2013; 13:20
- 10 510 Zahur-ur-Rehman A, Alam M. Platelet transfusion practice in a tertiary care hospital. *Journal*
11 *of the College of Physicians and Surgeons--Pakistan*. 2002; 12(8):485-487
- 12 511 Zakout G, Greiss MA. A 10-year look-back on use of cryoprecipitate in a tertiary care hospital.
13 *Haematologica*. 2009; 94:281
- 14 512 Zaporozhan V, Tarabrin O, Gavrychenko D, Mazurenko G, Saleh O, Lyoshenko I. Efficacy of
15 tranexamic acid in decreasing blood loss during cesarean section. *Critical Care*. 2013; 17:S135-
16 S136
- 17 513 Zhang H, Chen J, Chen F, Que W. The effect of tranexamic acid on blood loss and use of blood
18 products in total knee arthroplasty: a meta-analysis. *Knee Surgery, Sports Traumatology,*
19 *Arthroscopy*. 2012; 20(9):1742-1752
- 20 514 Zhang Y, Fu X, Liu WX, Li YM, Ma XL, Li ZJ. Safety and efficacy of intra-articular injection of
21 tranexamic acid in total knee arthroplasty. *Orthopedics*. 2014; 37(9):e775-e782
- 22 515 Zhao-Yu C, Yan G, Wei C, Yuejv L, Ying-Ze Z. Reduced blood loss after intra-articular
23 tranexamic acid injection during total knee arthroplasty: a meta-analysis of the literature.
24 *Knee Surgery, Sports Traumatology, Arthroscopy*. 2014; 22(12):3181-3190
- 25 516 Zhaohui L, Wanshou G, Qidong Z, Guangduo Z. Topical hemostatic procedures control blood
26 loss in bilateral cemented single-stage total knee arthroplasty. *Journal of Orthopaedic*
27 *Science*. 2014; 19(6):948-953
- 28 517 Zheng SR, Chi GZ. Effects of tranexamic acid on decreasing blood loss within two hours after
29 delivery. A multicenter randomized comparative study. *Blood*. 2000; 96:846a
- 30 518 Zhou XD, Tao LJ, Li J, Wu LD. Do we really need tranexamic acid in total hip arthroplasty? A
31 meta-analysis of nineteen randomized controlled trials. *Archives of Orthopaedic and Trauma*
32 *Surgery*. 2013; 133(7):1017-1027
- 33 519 Zhu DM, Shen J. The effect of tranexamic acid on hemostasis in pediatric cyanotic cardiac
34 surgery. *Cardiology in the Young*. 2010; 20:124-125
- 35 520 Zijlker-Jansen PY, Janssen MP, Wiersum-Osselton JC, Van Tilborgh-De Jong AJ, Schipperus MR.
36 Quality indicators for the hospital transfusion chain: a survey conducted in the Dutch
37 hospitals. *Vox Sanguinis*. 2013; 105:279
- 38 521 Zilberberg MD, Shorr AF. Effect of a restrictive transfusion strategy on transfusion-attributable
39 severe acute complications and costs in the US ICUs: a model simulation. *BMC Health Services*
40 *Research*. United States 2007; 7:138

1 522 Zumberg MS, del Rosario ML, Nejame CF, Pollock BH, Garzarella L, Kao KJ et al. A prospective
2 randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic
3 stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. *Biology of Blood and*
4 *Marrow Transplantation*. 2002; 8(10):569-576

5

6